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Metallopeptides As Model Systems for the Study of Cu(II)-Dependent Oxidation 
Chemistry 
 
 
 
William Maung Tay 
 
 
ABSTRACT 
 
 
 
 Copper is one of the essential metal ions for aerobic organisms.  Two well known 
functions of copper in the biological systems are electron transfer and molecular oxygen 
interaction.  Thus, this metal can be found in haemocyanin, an oxygen carrier protein, and 
superoxide dismutase, an enzyme that involves in electron transfer.  In addition, having a 
positive redox potential allows copper to be involved in redox chemistry.  It is the redox 
properties of copper that are responsible for many important biochemical processes.  
Although the copper-containing oxidases have been well studied over the years, certain 
mechanistic details such as reaction intermediates remain to be elucidated.  Several 
research groups have been trying to study this by trying to mimic the native systems, 
synthesizing bulky organic molecules with copper-binding and oxidative capabilities.  
However, these model systems are only applicable in organic solvents at low 
temperatures.  In this study, three naturally occurring peptides, amyloid-β, bacitracin, and 
 xii
 xiii
histatin 5, have been shown to display the oxidative chemistry when complexed with 
CuII.  A combination of spectroscopic (UV-Vis and NMR) and reactivity was used in 
studying their metal-binding properties as well as in elucidating their catalytic 
mechanism.  
  
 
 
 
CHAPTER 1 
 
COPPER-OXYGEN CHEMISTRY:  A BRIEF OVERVIEW 
 1
1.1 Introduction 
 Copper is essential for various biological processes, but can be very toxic when 
presence in excess.  Some of the biological processes that involve Cu are antioxidant 
defenses, pigmentation, mitochondrial respiration, neurotransmitter synthesis, connective 
tissue formation, peptide amidation, and iron metabolism.1  As a result, it is strictly 
regulated.  Disturbances in this delicate balance can lead to detrimental disorders such as 
Menkes (i.e.  Cu deficiency)2 and Wilson (i.e.  Cu excess) disease.3  In the case of Cu 
deficiency, the inability to incorporate this metal into important enzymes like dopamine 
β-monooxygenase and Cu,Zn-superoxide dismutase reduces the body’s ability to 
synthesize neurotransmitters and defend against oxidative stress, respectively.  Thus, the 
clinical symptoms of Menkes disease are neurological defects (such as severe metal 
retardation and neurodegeneration), growth retardation, hypothermia, and 
hypopigmentation.4  On the other extreme, the complications in Wilson disease are due to 
inability to remove Cu, leading to accumulation of Cu in the liver and brain.  As a result, 
the victim typically suffers from liver failure and neurodegeneration.5 
 The toxicity of Cu is partially associated with its potential to bind and activate 
dioxygen (O2), leading to generation of reactive oxygen species (ROS).6  Ironically, the 
same harmful chemical property of Cu is the one that has enabled us to survive and 
evolve into multicellular organims under the oxidizing conditions of the Earth’s 
atmosphere.7  This is evident in the essential involvement of Cu in O2 transfer (i.e.  
hemocyanin), energy production (i.e.  cytochrome oxidase), and antioxidation (i.e.  
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Cu,Zn-superoxide dismutase).  The versatility and reactivity of Cu is largely owing to its 
flexibility in ligand binding by both possible oxidation states (i.e.  CuI and CuII).7  Thus, 
it is essential to understand the redox chemistry of Cu with respect to how the O2 is 
activated in order to better understand its pathological roles. 
 In this respect, a general overview of Cu-O2 chemistry on selected dinuclear and 
mononuclear Cu centers in biological systems will be discussed herein.  Then, a brief 
discussion of progresses in the study of Cu-O2 chemistry using biomimetic approach 
through synthetic model complexes will follow.  Finally, the chapter is concluded with an 
introduction to metallo-peptides with a relevance to Cu oxidation chemistry. 
 
1.2 Cu Proteins 
Copper in biological systems can be classified into three groups named type I, 
type II, and type III.20c  Type I Cu consists of a group of small mononuclear Cu-
containing proteins known as the “blue Cu proteins”, owing to their visible intense blue 
color.  This intense color is a result of a ligand-to-metal charge transfer between sulfur of 
Cys to CuII.8  A typical ligand environment of type I Cu consists of two His, one Cys, 
and an axial Met through a distorted tetrahedral geometry.  These blue Cu proteins are 
mainly involved in a single electron transfer processes.  Type II Cu proteins contain a 
regular tetragonally distorted Cu ceter and can bind to a variety of amino acids to give 
different coordination geometry.  These Cu proteins can participate in oxidation and 
oxygenation chemistry.19c  Type III Cu systems are composed of two CuII bridged by 
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H2O or OH–, and the two CuII ions are antiferromagnetically coupled.  Type III Cu 
proteins can also be involved in oxidation and oxygenation chemistry.9 
 
1.2.1 Dinuclear Cu Proteins 
Tyrosinase, Catechol Oxidase, and Hemocyanin.  Tyrosinase is a type III di-CuII 
protein ubiquitously expressed in nature.10  The molecular weight of tyrosinase can vary 
from 14 to 43 kDa depending on the source.11  In plants, sponges, arthropods, and many 
invertebrates, they are involved in wound healing and primary immune response.12  In 
mammals, they are expressed in melanocytes of the retina and skin and are responsible 
for melanin formation.13  Furthermore, this enzyme is the cause of fruit and vegetable 
browning.   
By activating molecular oxygen, tyrosinase can exhibit two types of activities 
toward phenol-containing substrates:  cresolase or monophenolase activity and 
catecholase or diphenolase activity.  The di-Cu center can be in four different states:  
CuICuI (deoxy); CuICuII (half met); CuII-OH–-CuII (met); and CuII-O22–-CuII (oxy).11  In 
the met state, the CuII centers are bridged by OH–; whereas, the O22– serves as a bridge in 
the oxy state.  The cresolase activity requires the oxy state, while the catecholase activity 
can occur through either the met in the presence of H2O2 or oxy state.  In the cresolase 
activity, the phenol substrate is hydroxylated at the ortho position to give a catechol, 
which can be further oxidized to o-quinone (catecholase activity).11  A crystal structure of 
tyrosinase from Streptomyces Castaneoglobisporus is recently proposed with a small 
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protein bound to the active site.14  This protein named ORF378 is suggested to be 
important for crystallization and insertion of CuII ions into the active site of tyrosinase.  
The overall structure of tyrosinase is α-helical and both CuII ions are coordinated by 3 
histidine residues.  From the crystal structure, the distances between different states are 
4.1, 3.3–3.9, and 3.4 Å for the deoxy, met, and oxy states, respectively.14 
According to the proposed mechanism for tyrosinase (Figure 1.1),15 oxygen 
initially binds to the deoxy di-CuII center in a side-on binding mode, forming a peroxo-
bridged di-CuII center.  In the monophenolase or cresolase activity, the phenolic substrate 
binds to one of the CuII atoms in the axial position (Figure 1.1).  The CuII center is then 
rearranged to place the ortho position of the substrate closer to one of the peroxo oxygen 
for hydroxylation.15  The phenolic substrate is proposed to be subsequently hydroxylated 
by mechanism consistent with electrophilic aromatic substitution, forming a diphenol or 
catechol.  In the diphenolase or catecholase activity, the catechol substrate binds to both 
CuII at the same time and oxidized and released as o-quinone (Figure 1.1).  Finally, the 
deoxy di-CuI site is regenerated by the release of bridging OH as water.15 
Catechol oxidase, also known as o-diphenol oxidase and 1,2-benzenediol oxygen 
oxidoreductase, catalyzes the conversion of catechol to o-quinone.16  This enzyme can be 
found in plant tissues, insects, and crustaceans.17  Like tyrosinase, the molecular weight 
of catechol oxidase ranges between 30 and 60 kDa, depending on the source.  Based on 
extended X-ray absorption fine structure (EXAFS) and X-ray absorption near edge 
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structure (XANES) studies, the distances between the CuII ions are 2.9 and 3.8 Å for met 
and oxy states, respectively.18 
Hemocyanin, a structurally related protein to tyrosinase and catechol oxidase, is 
an oxygen carrier in arthropods and mollusks.  Hemocyanin has also been proposed to 
form a large protein aggregate with up to 8 MDa.19  Although the di-CuII center is 
conserved among all three proteins, each protein has a different function.  While 
hemocyanin is involved in O2 transfer, both catechol oxidase and tyrosinase can perform 
the oxidation of catechol to o-quinone, whereas tyrosinase also has a monophenolase 
activity.  The presence of an amino acid residue (which varies among different species) in 
the active site of hemocyanin and catechol oxidase has been proposed to be correlated to 
the inability to perform cresolase activity of tyrosinase.   
 
1.2.2 Mononuclear Copper Proteins 
Cu,Zn-Superoxide dismutase.  Copper-zinc superoxide dismutase (Cu,Zn-SOD) is 
an enzyme containing a type-II mononuclear Cu center, essential for catalyzing the 
decomposition of the highly reactive superoxide (O2–) to O2 and H2O2.20  It is expressed 
in both bacteria and eukaryotes.21  In bacteria, this enzyme is found in the periplasmic 
space.21e, f  In eukaryotes, Cu,Zn-SOD is largely found in the cytosol, nuclei, lysosomes, 
peroxisomes, and intermembrane space of mitochondria.21a–d  However, most structural 
and mechanistic studies are done on the eukaryotic forms (yeast, bovine, and human) of 
the enzyme.22   
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Figure 1.1.  Proposed Mechanism for tyrosinase.15  The monophenolase activity (or 
phenol o-hydroxylation) only occurs through the oxy state of di-Cu center; whereas, the 
diphenolase (or catecholase activity) can occur through both the met and oxy states of the 
di-Cu center. This illustration is adopted from ref. 15.   
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 Figure 1.2.  Crystal structure of two oxygen-binding functional units of Octopus 
hemocyanin (PDB ID:  1JS8).23  The giant protein is composed of 10 subunits, and each 
subunit is consisted of 7 oxygen-binding functional units.  The blue spheres represent Cu 
atoms, and the black spheres are oxygen atoms bound in a side-on mode.  
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The human form of Cu,Zn-SOD is composed of homodimers of 32 kDa, in which 
each has one CuII and one ZnII atom.24  Each domain is composed of eight stranded β-
sheets forming a Greek key β-barrel and three extended loop regions (Figure 1.3).  In its 
oxidized form, the CuII is penta-coordinated by four histidine residues (i.e.  His-46, His-
48, His-63, and His-120 in human form) in a distorted square planar coordination and a 
weakly axial-coordinated water at 2.5 Å away from the metal.  The ZnII ion is located 
approximately 6.6 Å from the CuII, and the two metals are bridged by the imidazole 
nitrogens of His-63.  The ZnII atom is coordinated by His-63, His-71, His-80, and Asp-83 
in a nearly tetrahedral geometry.20  Furthermore, the active site is stabilized by extensive 
network of hydrogen bonds.  The dismutation of O2– to occur at the CuII center.  
However, the ZnII binding has been proposed to help position the amino acid residues 
Glu-132, Glu-133, and Lys-136 in the correct conformation for substrate recognition.25 
 In general, the dismutation process can be explained in two parts (Eq. 1 and 2).  In 
the first part, CuII is reduced to CuI by one O2– molecule.  According to a proposed 
mechanism, the superoxide is initially non-specifically protonated to give a hydroperoxyl 
radical (HO2•) (Figure 1.4).26  Then, the bond between CuII and the imidazole group is 
broken upon HO2• binding to the CuII center.  The hydroperoxyl radical is deprotonated 
upon binding, followed by the protonation of the imidazole nitrogen.  Next, an electron is 
transferred to the CuII center to afford CuI and O2 (Figure 1.4 c).  In the second part, CuI 
is reoxidized to CuII by another HO2• molecule.26  Upon binding to the CuI,  
 9
 Figure 1.3.  Crystal structure of Cu,ZnSOD with the two metal center shown in ball and 
stick configuration (PDB ID:  2c9v).27  ZnII and CuII are displayed in green and orange, 
respectively. 
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HO2• is reduced to hydroperoxide while CuI is oxidized to CuII.  Finally, the 
hydroperoxide is protonated to give hydrogen peroxide by the proton from the imidazole 
group of His-63 (Figure 1.4 f).  The deprotonated imidazole group then can bind to CuII 
and bridge the two metal centers. 
CuIIZnIISOD + O2 CuIZnIISOD + O2 (1) 
CuIZnIISOD + O2 + 2H+ CuIIZnIISOD + H2O2 (2) 
Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disorder 
where 20–25% of familial ALS, has been associated with mutations in the Cu,Zn-SOD 
gene, sod1.  Over 100 mutations of sod1 have been identified, which ranges from amino 
acid substitutions to frameshifts.28  Furthermore, protein aggregates containing mutant 
Cu,Zn-SOD have been found from ALS patients, ALS transgenic mice, and cell culture 
model systems.29  Currently, there is no cure for this devastating disease. 
 
Peptidylglycyine α-Hydroxylating Monooxygenase (PHM) and Dopamine β-
Monooxygenase (DβM).  Peptidylglycine α-hydroxylating monooxygenase (PHM) 
and dopamine β-monooxygenase (DβM) are another group of proteins with mononuclear 
Cu center.30  While PHM hydroxylates C-terminal glycine-extended peptides, DβM 
converts dopamine to norepinephrine by hydroxylating the β carbon.  Both enzymes are 
exclusively expressed in higher eukaryotes, and their primary sequences are 27% 
identical and 40% similar.31  PHM and DβM can be found in the secretory vesicles of the 
pituitary gland32 and the chromaffin granules of the adrenal gland,33 respectively.   
 11
 Figure 1.4.  Mechanism of Cu,Zn superoxide dismutase.  This illustration is adapted 
from ref. 4.  Steps a–c constitute disproportionation on one O2– molecule, where the 
oxidation state of Cu is 1+ and the imidazole nitrogen is protonated.  Steps d–f account 
for catalysis of a second O2– molecule. 
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Each enzyme contains two CuI sites, which are 11 Å apart (Figure 1.5).34  In 
PHM, the copper centers are named CuH and CuM (i.e.  in DβM, CuH = CuA and CuM = 
CuB), and CuM has been proposed to be the site of substrate and oxygen interaction.  On 
the other hand, CuH is suggested to be involved in electron storage and transfer.  As a 
result, PHM and DβM are considered as mononuclear Cu proteins during their catalysis.  
Furthermore, the amino acids involved in Cu binding are highly conserved between them.  
The CuH atom is coordinated by three histidine residues, whereas CuM is bound by two 
histidine and a methionine residue.30, 34 
According to the proposed hydroxylation mechanism (Figure 1.6), the substrate 
binds close to the CuM site and not at the metal center.30  Upon O2 binding to CuM, an 
electron is transferred from the Cu atom to O2 to afford CuIIO2– species.  Then, a proton-
tunneling occurs from the substrate to the CuIIO2– complex to give CuIIOOH 
(hydroperoxo) complex.  At this stage, two pathways have been proposed.  In the first 
proposal, the electron from CuH reductively cleaves the hydroperoxo complex to give 
CuMIIoxo radical, which reacts with the substrate-derived radical to give alcohol 
product.35  The second route involves a direct hydroxyl radical abstraction by the 
substrate-derived radical to afford CuMIIoxo, which is then reduced by the electron 
transfer from the CuH atom to afford CuMIIOH.36  Finally, CuI is regenerated by ascorbic 
acid.30 
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 Figure 1.5.  Crystal structure of peptidylglycine α-hydroxylating monooxygenase (PDB 
ID:  3PHM).37  The two Cu atoms are displayed in orange, and they are ~11 Å from each 
other.  In addition, they are fully exposed to solvent and yet the electron transfer from 
CuH (right orange sphere) occurs to CuM (left orange sphere).
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 Figure 1.6.  Proposed mechanism for peptidylglycine α-hydroxylating monooxygenase 
and dopamine β-monooxygenase.  This illustration is adapted from ref. 30. 
 15
1.3 Biomimetic Synthetic Model Complexes 
Even among the type III di-Cu proteins with a very well conserved active site, 
such as hemocyanin, catechol oxidase, and tyrosinase, nature has fine-tuned them to 
function differently.  While the same di-Cu center is used for reversible O2 transfer in 
hemocyanin, this active site is also applicable in both o-hydroxylation of phenol to 
catechol and oxidation of catechol to o-quinone in tyrosinase and the latter in catechol 
oxidase.  These three are only a few of many Cu-containing proteins that are involved in 
oxidation and oxygenation chemistry.  The interactions between O2 and different types of 
Cu centers vary, and the reaction mechanism can become complicated with respect to the 
active site environment.   
These structural and mechanistic complexities have long interested inorganic 
chemists such as the late Nobumasa Kitajima, William B. Tolman, Shinobu Itoh, and 
Kenneth D. Karlin just to name a few.  Their approaches have been to elucidate the O2 
intermediates during catalysis by Cu proteins through synthetic organic complexes that 
mimic the protein active site.  Since histidine is the most common ligand in Cu proteins, 
most of these synthetic ligands contain nitrogen, involved in Cu binding.  Their findings 
have made significant contributions in understanding the O2 chemistry of Cu proteins.  A 
classic example is the very first crystal structure of a di-CuII-peroxo complex supported 
by the [(HB(3,5-iPr2pz)3)]2 ligand with O2 bound in a side-on binding mode determined 
by Kitajima and co-workers in 1989.38  Prior to his discovery, the end-on binding 
between the two Cu centers had been well accepted for O2 binding to the active site of 
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hemocyanin.  He revealed that oxygen binds between the two Cu centers in a side-on 
mode.38  His finding was also demonstrated 5 years later on oxy-hemocyanin from 
arthropod with X-ray structural determination.39  Since then, many (μ-η2:η2-peroxo)Cu2II 
complexes of different bidentate and tridentate nitrogen ligands have been synthesized 
and studied.40 
Although a catalytic mechanism of tyrosinase has been proposed,41 the O2 
transfer from the dinuclear CuII-peroxo center to phenol (i.e.  o-hydroxylation or 
monophenolase activity) still has not been well explained.  This step of the mechanism
has been long investigated with dinuclear CuII model systems.
 
dication 
olate 
the 
42  One common finding is 
the formation of C-C coupled dimer at the ortho position of phenol.  This is the in
that phenoxyl radicals have been generated.  Since there are two possible O2 binding 
modes, end-on bis(μ-oxo) and side-on (μ-η2:η2), a bidentate (LPy1) and a tridentate (LPy2) 
ligand that give end-on and side-on complexes (Figure 1.7), respectively, are used to 
determine the hydroxylation step of the mechanism in a recent study.43  Using phen
as a substrate in organic solvent at –94 °C, the dinuclear CuII-peroxo complex gives 
oxygenated product catechol, whereas, using neutral phenol only resulted in the dimer 
product.  However, the μ-oxo complex does not give catechol regardless of the type of 
substrate used.  By correlating the kinetic data to the oxidation potential of the substrate, 
the authors to propose the hydroxylation to occur through an electrophilic aromatic 
substitution mechanism.43 
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Unlike dinuclear Cu-O2 complexes, the studies of mononuclear Cu-O2 complexes 
have a big short coming.  This is due to a higher tendency of CuI and O2 to form stable 
dinuclear Cu-O2 complexes.40b  However, a number of mononuclear Cu-O2 complexes 
have been prepared based on spectroscopic evidence and structure determined.44  
Transient mononuclear end-on CuII-superoxo complexes with tripodal tetradentate 
ligands such as TPAR and trenR, R′ (Figure 1.8) have been observed to show a strong 
absorption at ~410 nm prior to assembling into (trans-μ-1,2-peroxo)CuII2 complexes.45  
The resonance Raman results from isotope-labeling experiments indicate these 
intermediates have stretching vibrations at ~1120 cm–1 (ν = 16O–16O) and ~60 cm–1 (ν = 
16O–18O), which have been suggested to be consistent with the formation of CuII-
superoxo.45  Kitajima and co-workers have successfully isolated and characterized a 
mononuclear side-on CuII-superoxo complex with the ligand HB(3-tBu-5-iPrpz)3– (Figure 
1.8), a monoanionic tridentate ligand having a bulky alkyl substituents.46   
Other mononuclear Cu-O2 complexes have been proposed, but spectroscopic 
results alone are not enough to unambiguously assign the oxygen intermediates in some 
cases.47  In general, both the size of the attached groups48 and the hydrogen bonding 
interaction49 between the oxygen and ligand help stabilize the complex.  Nevertheless, 
most of these mononuclear Cu-O2 complexes are inactive toward external substrates.50  
Although slow, progress has been made in characterization of mononuclear Cu-O2 
complexes with the help of a low-temperature stopped-flow technique.51 
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Figure 1.7.  End-on versus side-on binding mode (top) and a bidentate (LPy1) versus a 
tridentate (LPy2) ligand (bottom).43 
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Figure 1.8.  Ligands used for the preparation of Cu complexes:  TPAR (Karlin);45b 
trenR,R’ (Tolman);40b HB(3-tBu-5-iPrpz)3– (Kitajima).46
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1.4 Metallopeptides 
Recently, there is a new interest in the study of peptides with metal binding 
capabilities, owing to their versatile nature, in which de novo sequences can be generated 
to exhibit various functions.  Some of their well known functions are DNA/RNA 
recognition and cleavage,52, 57, 58 heavy metal binding,53 antibacterial and antifungal 
activities,54 and fluorescent probes.55  These peptides contain one or more metal binding 
sites which increase the stability of the overall complex or provide the active site for 
various catalyses.56 
Cowan and co-workers have shown one of many potential applications of 
designed metallopeptides in DNA and RNA recognition and cleavage.57, 58  In a recent 
study, they have constructed polypeptides ranging from 21–27 amino acid residues 
containing N-terminal ATCUN (Amino Terminal CUII and NiII binding)59 metal binding 
motif and C-terminal HIV Rev response element (RRE) RNA recognition peptide with a 
glycine linker with different lengths.58  Then, a green fluorescent protein is co-expressed 
with RRE RNA in the N-terminus of the DNA oligonucleotide sequence in pET-21 
plasmid vector in E. coli..  The CuII complexes of ATCUN-RRE RNA recognition 
peptides are included during the expression.  The damage of RRE RNA is determined 
based on the decrease in fluorescence intensity, which reflects the population of 
translatable mRNA.  Significant reduction in the fluorescence intensity is observed only 
in the presence of CuII-ATCUN-RRE RNA complexes and not ATCUN or RRE RNA 
sequences alone.58  In addition, Cowan and co-workers have shown the damage of 
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polynucleotides by CuII complexes of short ATCUN peptides is through oxidative 
cleavage.57 
In a study by Imperiali et al., the versatility and specificity of synthetic peptidyl 
templates are well exploited.55  A family of peptides is designed, modeled after the Zn 
finger domain,60 to be used as a fluorescent sensor specifically toward ZnII ions.  The 
chemosensor is composed of a Zn finger domain, an L-β-amino alanine, and a 
fluorophore.  The L-β-amino alanine is essential for the incorporation of the fluorophore.  
Before removing the newly synthesized polypeptide, the L-β-amino alanine can be 
selectively deprotonated with a PdII catalyst under mild conditions.61  Then, the 
fluorophore can be coupled to L-β-amino alanine.  Thus, incorporation of L-β-amino 
alanine in any part of the sequence also enables the attachment of the fluorophore at any 
desired part of the peptidyl sequence.  Since Zn fingers have been known to undergo 
metal-induced reversible folding,62 the chelation can be sensitively detected by placing 
the fluorophore close to the hydrophobic residues, which potentially involve in the 
folding process.  As a result, the binding of ZnII ions to the Zn finger motif is reported to 
show great sensitivity.  Due to the high ZnII binding affinity of the Zn finger domain, the 
specificity can be achieved.55 
The above two studies clearly illustrate the versatility, specificity, and 
applicability of peptide templates in studies involving metal ions.  In the same respect, I 
have proposed the use of three naturally occurring peptidyl systems in studying the CuII-
O2 chemistry with relevance to their biological activities in the following chapters.  The 
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peptides of interests are short N-terminal amyloid-β fragment, Aβ1–20 (the full length 
peptide found in the plaques isolated from the brain of Alzheimer’s patients.), bacitracin 
(a metal binding peptide antibiotic with specificity toward Gram positive bacteria.), and 
histatins 5 peptide (a salivary peptide with high potency toward the opportunistic yeast 
Candida albicans).  In chapter 2, the possible therapeutic effect of a naturally occurring 
flavonoid, quercetin, toward metal-centered oxidation chemistry of CuIIAβ1–20 is 
presented.  Then, in chapters 3 and 4 the oxidation chemistry of CuII complexes of 
bacitracin and histatin 5 are discussed. 
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CHAPTER 2 
 
 
ANTIOXIDATIVE PROPERTIES OF A NATURALLY OCCURRING 
FLAVONOID, QUERCETIN:  IMPLICATIONS TOWARD TREATMENT 
STRATEGIES FOR ALZHEIMER’S DISEASE 
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2.1 Amyloid–β 
Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder that mainly 
affects the elderly population and currently without a cure.  The average age-onset is 60, 
and the risk increases with aging.  According to the National Institute of Health, as many 
as 4.5 million Americans suffer from this disorder.1  While approximately only 5% of the 
population between the ages 65–74 has this disease, up to 50% have been estimated for 
the age group 85 and older.  AD is characterized by a progressive deterioration of the 
brain; the average life-span of the diagnosed individuals is 5–10 years, although some 
may live up to 20 years.  It is a memory disorder, initially characterized by inability to 
recall recent events.  As the disease progresses, memory loss and cognitive impairments 
become a part of the patient’s daily life.  AD was initially recognized by Dr. Alois 
Alzheimer in 1906.  He discovered a noticeable amount of tissue masses accumulated in 
the brain of a female patient, suffering from a strange mental illness.  These masses were 
later termed amyloid-β plaques.1 
Amyloid-β (Aβ) is a proteolytic product of amyloid precursor protein (APP), 
consisting of 39–42 amino acids, and aggregation of this peptide in the brain is the 
hallmark of Alzheimer’s disease.2  APP is a membrane-bound synaptic protein, where the 
N- and C-terminal ends are extracellularly and intracellularly situated, respectively.3  In 
addition, APP has two evolutionarily related cousins, APLP-1 and APLP-2, in 
mammals.4  All three synaptic proteins are essential for developmental and postnatal 
functions, as have been shown by the double and triple knock-out studies in mice.  
 39
Cranial abnormalities and early postnatal lethality are two phenotypes common among all 
knock-out studies.5  Different proteolytic cleavage of APP by secretases decide the fate 
of Aβ.  The sequential processing of APP by β- and γ-secretases results in th
amyloidogenic and toxic form of Aβ, while the proteolytic product of α-secretase is 
considered non-toxic since this enzyme cleaves APP within the Aβ peptide.
e 
6  The full 
length peptide can be further cleaved into small soluble fragments (e.g.  Aβ1–16) from the 
N-terminal end by α- and β-secreatases7 as well as insulin-degrading enzyme.8 
Despite extensive studies, the physiological function of Aβ is still unclear.  
Nevertheless, a commonality in the brains of postmortem AD patients is the presence of 
plaques, resulted from the aggregated Aβ peptide.  The two most common forms of Aβ 
peptide are 1–40 and 1–42.  While the former is found in larger quantity, the latter is 
suggested to be more toxic.  The primary sequence of Aβ is as follows:  
DAEFRHDSGY10 EVHHQKLVFF20 AEDVGSNKGA30 IIGLMVGGVV40 IA.9  The Aβ 
peptide is amphipathic in nature, and its conformational state is influenced by a few 
factors, such as pH, temperature, and solvent environment.10  At pH < 4 or > 7, the 
peptide is suggested to remain as a monomeric form in α-helical or random coiled 
conformation.  Within the pH range 4–7, however, it becomes less stable and tends to 
form oligomers, which eventually lead to aggregation.  The N-terminal 20 amino acids 
are more hydrophilic and can adopt α-helical or random coil conformation in aqueous 
environment, depending on the conditions.10c, g  The C-terminus is quite hydrophobic and 
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is suggested to form stable β-sheet structures with a high tendency to aggregate, 
regardless of the conditions and environment.10g   
Furthermore, the plaques have been shown to contain a high concentration of 
metal ions such as CuII, FeIII, and ZnII, determined to be 390, 940, and 1055 μM, 
respectively.11  Comparing to the age-matched controls, the concentration of these metal 
ions in the brain of AD patients have increased 6, 3, and 3 times for CuII, FeIII, and ZnII, 
respectively.  All three metal ions can cause Aβ aggregations in vitro; a process that is 
reversed by metal chelator such as EDTA.12  Thus, it is important to determine the 
interaction of Aβ with metals.   
Contrary to exhaustive metal binding studies using numerous powerful 
spectroscopic techniques,13 the coordination environment is still under debate.  The 
matter is complicated by experimental variations such as solvent system, pH, and the 
length of peptide.  Nevertheless, it is generally accepted that only the N-terminal region 
(1–16 residues) of the Aβ peptide is involved in metal binding and that the affinity for the 
metal ion is in the micromolar range,13e, h although an earlier study suggested an 
attomolar affinity, which mistakenly combined a coagulation constant into the affinity 
constant.13g  The N-terminus contains three histidine (at positions 6, 13, and 14) and 
several acidic residues (Asp-1, Glu-3, Asp-7, and Glu-11) that can potentially involve in 
metal binding.  The involvement of all three His residues in CuII and ZnII binding is 
universally accepted.13, 63  The lack of AD in rats clearly demonstrates the involvement of 
these histidine residues in AD, since the rat variant of Aβ peptide contains the following 
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three mutations:  Arg-5 to Gly, Tyr-10 to Phe, and His-13 to Arg.14  The ability to bind 
metal is greatly reduced by the H13R mutation, and thus, rats do not suffer from AD.14  
In addition to the histidine residues, several candidates have been proposed to be the 
fourth ligand in metal binding, including the amino group of the N-terminal Asp-1,13d, e, f 
the phenolate group of Tyr-10,13c, g and the carboxylate group of Glu-11.13b 
According to the amyloid cascade hypothesis, the plaques are the culprits of 
neurodegeneration.15  However, this theory was quickly invalidated by postmortem brain 
analysis of AD victims.  There is a discrepancy between the amount of aggregates present 
and the severity of deterioration.16  Closer analysis of the plaques led to evidence of a 
possible oxidative stress in the brain.17   
Metal ions in biological systems are closely regulated, especially redox-active 
metals such as CuII and FeIII.22  The availability of Fe in cell involves two transporters, 
DMT1 (influx) and Ireg1 (efflux),18 and the extracellular transport and storage are 
responsible by high affinity binding transferrin and highly efficient ferritin, 
respectively.19  Similarly, the influx of CuII ions is performed by Ctr1, DCT1, and 
DMT1, while the excretion is controlled by Menkes (MNK) and Wilson (WND) 
ATPases.20, 21  In addition, the intracellular CuII concentration is highly regulated by 
multiple chaperone proteins.22  However, these regulatory processes lose efficiency wit
aging, leading to accumulation of the unbound metal ions.
h 
ically 
23  Redox-active metals such as 
CuII and FeIII can generate highly reactive hydroxyl (OH•) radical through Fenton 
chemistry in the presence of molecular oxygen.24  This radical can attack and chem
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modify biological molecules such as lipid molecules in membranes, amino acids in 
proteins, and nucleic acids (DNA and RNA), rendering them dysfunctional.17   
A recent study displaying the ability of Aβ to generate hydrogen peroxide (H2O2), 
a reactive oxygen species (ROS), in the presence of biological reducing agents and CuII 
confirms the involvement of redox chemistry in the etiology of AD.25  In fact, there is 
direct evidence of oxidative damages in the Aβ plaques.17  It is possible that oxidative 
stress leads to neurodegeneration, and the plaques are the end result of a protective role 
played by the Aβ peptide.26  The same has been proposed for other aggregate-forming 
neurodegenerative disorders, such as Prion-related and Parkinson’s diseases.27  In this 
proposed theory, the Aβ peptide attempts to chelate and remove the accumulated free 
pool of metal ions.  The situation is exacerbated instead when the CuII/FeIIIAβ complexes 
themselves can act as the redox centers to generate ROS.  The free and complexed 
peptides may be chemically modified and subsequently aggregated in the process.28  
Recent findings show the ability of APP to bind and reduce CuII, suggesting a role in CuII 
regulation of this protein.29  In addition, APP has been shown to be neuroprotective in 
vivo, further supporting the protective role of its C-terminal Aβ fragment.30  If the 
aggregated form of Aβ is the aftermath, the soluble or oligomeric form of the peptide is 
truly responsible for the redox chemistry.  In fact, recent studies have shown the 
oligomeric Aβ peptide to be more toxic.31  This explains the lack of consistency between 
the disease stage and the amount of Aβ aggregate. 
 43
In addition to oxidative stress, interference in the intracellular CaII homeostasis by 
Aβ was also suggested to contribute to the pathology of AD.32  Even though the 
dysfunction in CaII homeostasis does not play a role in the overall neurodegeneration, it is 
responsible for the cognitive impairments in AD.33  In the hippocampus, Aβ aggregates 
have been shown to span lipid membrane, creating channels with poor ion selectivity.34  
Moreover, the soluble forms of Aβ can cause membrane depolarization and impair 
Na+/K+-ATPase, which can lead to an increase in CaII influx.35,36  The rise in the CaII 
level defects neurons and synapses, deters long-term potentiation in certain brain regions, 
and leads to impairments in learning and memory.37  Thus, regulation of redox-active 
metals as well as CaII influx in the hippocampus is essential toward possible prevention 
and treatment of AD. 
We have recently reported that the CuII complexes of the shorter proteolytic 
fragments, Aβ1–16 and Aβ1–20, are able to perform two-electron oxidation of polyphenol, 
catechol, and phenol to their respective o-quinone products consistent with Type-3 
copper oxidases.38, 63, 64  In the proposed catechol oxidase-like mechanism (Figure 2.1),63 
the reducing substrate catechol can bind directly to the di-CuII center bridged by a 
hydroxyl group and readily oxidized into the corresponding ortho-quinone (Figure 2.1 
steps F and G).  This process involves 2e– transfers, and the di-CuII is reduced to 2CuI.  In 
the presence of dioxygen, the metals can resume its oxidized states by forming a 
dinuclear dioxygen-bound CuII complex, where the species present can be one of the 
three isoelectric states:  
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( ) +++ −−−−−−−− 32222112222 ,:,: CuoxoorCuperoxoCuperoxo μηημηημ (B in Fig. 
2.1). This peroxo-bridged di-Cu2+ center can go through another cycle of oxidation, 
before returning to its hydroxyl-bridged di-CuII following the concomitant release of one 
of the bound-oxygen as water (Figure 2.1 steps C and D).  In addition, in the presence of 
the peroxo-bridged di-CuII can form directly from the hydroxyl-bridged species (Figure 
2.1 steps A–D).63 
In the phenol-oxidase-like mechanism (Fig. 2.2),64 the phenol substrate initially 
binds to a CuII center, followed by a transfer of an electron to give a CuI-(phenol radical) 
intermediate (step a).  The radical is stabilized with the unpaired e– situated on the ortho 
and para positions.  Next, the binding of dioxygen to the CuI-phenol radical results in 
another electron transfer to afford a CuII superoxide structure (step b), which is 
potentially stabilized by binding of a second CuII center.  Finally, the o-quinone product 
is formed by the transfer of an electron and an oxygen atom to the semi-quinone (Figure 
2.2 steps c, d).  The possible involvement of di-CuII center was shown by diluting redox-
active CuII with the redox-inactive ZnII.64   
We also observed catecholamine neurotransmitters can be effectively oxidized by 
CuII-Aβ with and without H2O2.38  Thus, in the presence of CuII the Aβ peptide can 
potentially oxidize and deplete the catechol- and phenol-containing neurotransmitters (i.e.  
dopamine, serotonin, epinephrine, and norepinephrine) in the brain, causing neuronal 
death.  The fact that oxidative stress is a metal-dependent process raises a new interest in 
metal-chelation therapy as a treatment for AD. 
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 Figure 2.1.  Proposed mechanism for CuII-centered oxidation of catechol-containing 
substrates in the presence (A–D) and absence (F–H and B–D) of H2O2.63 
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Figure 2.2.  Proposed mechanism for the CuII-centered hydroxylation and oxidation of 
phenol-like substrate(s):  (a) binding and electron transfer to the phenol substrate from 
the CuII center to give a CuI-phenol radical; (b) dioxygen and a second CuII center 
binding; (c) transfer of an electron and an oxygen atom to the phenol to result in an o-
quinone product (d).64 
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One of the current treatment strategies toward AD rely on metal chelation as a key 
step in preventing the aggregated Aβ plaques from forming, such as the use of CuII 
chelator clioquinol (5-chloro-7-iodo-8-hydroxyquinoline).39  This drug was banned from 
its original usage in 1970 as an antibiotic due to a severe side effect, subacute myelo-
optic neuropathy, in the central nervous system.40  This toxicity has been explained to be 
the result of CoII chelation by clioquinol from Cobalamine, leading to vitamin B12 
deficiency.  In a transgenic mice treatment study, clioquinol has been shown to alleviate 
up to 49% Aβ deposition, accompanied by a small increase in the concentration of 
soluble Aβ.41  A recent Phase II clinical trial involving 36 patients suggests this drug to 
be more effective toward those with greater disease severity.  In this study, one of the 
clioquinol-treated subjects suffered from dysfunction in visual acuity and color vision 
with the symptoms go away upon discontinued treatment; two other patients suffered 
from leg numbness.42   
In addition, an earlier study by Yagi et. al. has shown clioquinol can induce lipid 
peroxidation in cultured chick retinal cells in the presence of iron.43  A recent study 
supports the pro-oxidant activity of this drug by the killing of cultured neuronal cells in 
the presence of redox-active FeIII and CuII, and 90% cell viability was recovered in the 
presence of vitamin C and Trolox C.44  Thus, clioquinol, possessing these intrinsic 
toxicities, may not be suitable for use as a therapeutic treatment toward AD.  Since 
oxidative stress in different regions of the brain is the underlying theme among the 
neurological pathologies, the possibility of using naturally occurring powerful 
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antioxidants from plants has become an increasingly popular interest.45, 59a  One family of 
these antioxidative secondary plant metabolites are flavonoids.  
 
2.1.1 Flavonoids 
 Flavonoids are polyphenolic compounds ubiquitously distributed in plants.  They 
display antimicrobial and antifungal properties, which largely contribute toward growth 
and development of plants.46  They show various beneficial biological activities such as 
antihepatotoxic, antiinflammatory, antiatherogenic, antiallergenic, antiosteoporotic, 
anticancer, and neuroprotective properties.47  These biological activities can be credited 
to their involvements in signaling,48 interaction with enzymes,49 and ability to scavenge 
free radicals50 and chelate metal ions.51  Flavonoids have gained intense interest because 
of their consumptions through fruits, vegetables, and related food products, which can be 
correlated to a better health (e.g.  reduce the risk of cardiovascular diseases).52  Many in 
vitro studies have shown antioxidant and antitumor capabilities of flavonoids toward 
multiple cell lines.47  Moreover, they have a large variation in functional groups, 
rendering them useful for applications as templates toward future drug design.  However, 
the molecular basis and mechanism of the antioxidation activity of the structurally 
diverse flavonoids and their capability of scavenging free radicals have not been 
conclusively revealed.  In general, the phenoxyl groups on the flavonoids have been 
associated with radical scavenging property.50, 53  Thus, those with a higher number of 
hydroxyl substituents are considered better antioxidants. 
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Quercetin (Qr), 3,3',4',5,7-pentahydroxyflavone, is one of the extensively studied 
flavonoids with potent antioxidant activity (Figure 2.3 I).51, 52  It is largely found in apple, 
onion, tea, red wine, blue berry, and grape.54  The structure of Qr contains a hydroxylated 
pyrone ring (C ring) conjugated to a meta-diphenolic ring (A ring) and an ortho-
diphenolic ring (B ring).  Like most flavonoids, Qr has the ability to scavenge free 
radicals and chelate metal ions.  Studies have shown that Qr binds metal ion(s) in a 
bidentate manner.51b,d  There are three possible metal-binding sites on quercetin:  β-keto-
phenolate (4-carbonyl and 5-phenolate), α-keto-enolate (4-carbonyl and 3-enolate), and 
catecholate (3'- and 4'-phenolate) moiety (Figure 2.3 I).  The metal-binding ability of Qr 
has been extensively studied with potentiometric and different spectroscopic techniques, 
using alkaline-earth (i.e.  CaII and MgII), transition (i.e.  CuII and FeIII), and lanthanide 
(i.e.  YbIII) metal ions.  Nevertheless, the coordination environment and metal binding 
modes have not reached consensus.51   
  The redox-active metal dependent oxidative stress is proposed to be the culprit of 
neurodegeneration in the pathology of AD.  We have confirmed this by showing the 
catechol- and phenol-oxidase-like chemistry of small Aβ fragments in the presence of 
redox-active CuII in vitro.38, 63, 64  Thus Qr, with its radical-scavenging and metal-
chelating properties, is one of many candidates as an inhibitor toward the metal-induced 
oxidative stress. 55  Qr can potentially degrade the ROS generated by the oxygen-bound 
CuII center or can directly bind to the active CuII center to prevent further chemistry.   
The latter has been shown by the ability of Qr and related flavonoids in inhibiting the 
 50
OOOH
O
OH
OH
OH
OH
OH
I
II
O
O
OH
OH
OH
OH
OH7
5 4
3
3'
4'
A C
B
III
2'
5'
6'
6
8
 
Figure 2.3.  Structure of quercetin (I), 5-hydroxyflavone (II), and catechin (III).  There 
are three potential metal-binding sites on quercetin:  β-keto-phenolate (4-carbonyl and 5-
phenolate); α-keto-enolate (4-carbonyl and 3-enolate); and catecholate (3'- and 4'-
phenolate), while 5-hydroxyflavone only has the β-keto-phenolate moiety and catechin 
only possesses the catecholate moiety for metal binding. 
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 chemistry of tyrosinase, a dinuclear CuII-containing oxidase capable of converting 
phenol derivatives to o-quinone.56  Both Qr and kaempferol (a Qr analogue with a 
missing OH– group at 3' position) competitively inhibit tyrosinase activity, with an 
estimated IC50 values were 0.13 and 0.23 mM, respectively.57, 58  The mechanism of 
inhibition was suggested to be due to metal chelation at the active site.   
Qr along with several other flavonoids have been suggested to have 
neuroprotective properties.59  To better understand the neuroprotective activity of Qr, the 
redox chemistry and coordination properties must be clearly revealed to provide a 
relationship between their structures and activities.  In this study, the antioxidative 
mechanism of Qr toward the observed CuII-centered oxidation chemistry of Aβ was 
determined through optical, NMR, and reactivity studies.  The Aβ peptide and aggregates 
have been proposed to cause a rise in the intracellular CaII concentration, leading to 
memory loss and cognitive impairments in AD patients.  Thus, the metal binding 
properties of Qr and the influence of CaII on the antioxidative property of Qr was also 
determined. 
 
2.2 Materials and Methods 
The N-terminal amyloid-β (Aβ1–20) was synthesized at the University of South 
Florida Peptide Synthesis and Mass Spectometry Center and the accuracy and purity 
checked with a MALDI-TOF mass spectrometer.  Quercetin (Qr), Pyrocatechol, ~99% 
(CA), deuterated dimethyl sulfoxide d6-DMSO (99.9%), and 3-methyl-benzyl 
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thiazolinone hydrochloride (MBTH), the lanthanide(III) chloride salts (99.99%) and 
CaCl2 were purchased from Sigma-Aldrich Chemical Co. (Milwaukee, WI); CuSO4 and 
4-(2-hydroxyethyl)-1-piperazineethanesulfonate buffer (HEPES) from Fisher Scientific 
Co. (Fair Lawn, NJ); and CoCl2•6H2O from Mallinckrodt (Paris, KY).  All chemicals 
were used without further purification.  All other solvents and reagents were the highest 
grade available from the commercial sources.  The deionized water (18.2 MΩ) was 
obtained from a Millipore Milli-Q system.  Plasticware and glassware were demetallized 
with EDTA and extensively rinsed prior to use.   Due to the low solubility of Qr in 
aqueous solution, some experiments were performed in DMSO or d6-DMSO.  Both the 
metal and the ligand solutions were freshly prepared just prior to the experiments.  Quartz 
cuvettes were used in all the kinetic and optical measurements. 
 
2.2.1 Kinetic Studies 
The 1:1 CuIIAβ1–20 complex was prepared in deionized water.  The oxidation of 
catechol by 1.0–3.0 μM CuIIAβ1–20 in the presence or absence of different concentrations 
of Qr, CaII, and YbIII was monitored in 100.0 mM HEPES at pH 7.0 and 25 ºC.  Equal 
amounts of substrate and of the specific o-quinone indicator, MBTH, were used in the 
assay.60  All components were dissolved in DI water, and the final volume in the cuvette 
was fixed at 1.0 mL.  The formation of the quinone product was followed photometrically 
(ε = 32,500 M–1 cm–1 for o-quinone-MBTH complex)60 at 500 nm with a Varian 
CARY50 spectrophotometer equipped with a water peltier PCB-150 thermostable cell 
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(Varian, Palo Alto, CA), and the initial rate was determined from the slope of the change 
in the absorbance with respect to time (0–5 mins) in the linear region.  
Inhibition/activation of the reaction was performed with various amounts of an 
inhibitor/activator, and the rate determined and fitted to appropriate rate law to reveal the 
inhibition pattern.  Sigma Plot 8.0 was used for plotting and fitting the data. 
 
2.2.2 Optical Studies 
All optical studies were performed in DMSO; triethylamine (TEA) was added as 
needed to enhance metal binding to Qr.  The electronic spectra were acquired on the 
cary50 spectrophotometer.  For metal-binding studies, 20.0 μM Qr was added with 
different concentrations of metal to a total volume of 1.0 mL, and the mixture was 
monitored from 200–800 nm.  An optical Job plot61 can be utilized for revealing the 
metal-to-ligand stoichiometry, and has previously been demonstrated useful for the 
determination of complicated metal-drug binding stoichiometry.62  In the plot, a distinct 
absorption of the complex as a function of metal mole fraction (XM) or ligand mole 
fraction (XL) was obtained with a constant amount of the total concentration ([M] + [L]), 
wherein the ratio of XM:XL at which the absorption reaches the maximum in the plot 
reflects the stoichiometry of the M-L complex in solution.  For all the Job plot studies, 
the metal and ligand concentrations were varied from 0–20.0 μM while keeping the 
overall concentration constant. 
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2.2.3 NMR Studies 
1D and 2D 1H NMR spectra were acquired on a Varian INOVA500 spectrometer 
(at 500 MHz 1H resonance) with a 5-mm bio-TR (triple resonance) probe.  A 90° pulse 
(~5 μs) was used for the acquisition of 1D 1H NMR spectra with 8 K data points, whereas 
1024 × 512 data points were used for 2D EXSY (EXchanged SpectroscopY) experiment 
which reveals chemical exchange and the exchange pairs, with a presaturation pulse as 
well as superWEFT technique68 for solvent suppression.  In 1D 1H saturation transfer 
experiments to reveal chemical exchange, a signal of the exchange partners is saturated 
with a presaturation pulse, and the different spectrum is obtained from the irradiated and 
the reference spectra (the presaturation pulse was applied at a signal-free region of the 
spectrum).  A line-broadening of 40 Hz was applied to improve the signal-to-noise ratio 
of the paramagnetically shifted signals.  The spin-lattice relaxation times (T1) for the 
paramagnetically shifted signals were determined using the inversion-recovery method 
(τ1-180°-τ2-90°-FID).  The peak intensities versus the τ values were fitted with a three-
parameters fitting program on the spectrometer to afford the T1 values. 
 
2.3  Results and Discussion 
The presence of ZnII along with redox-active CuII and FeIII in amyloid plaques is 
evidence that AD is a metal-dependent pathology.  Numerous studies have shown the 
possible involvement of CuII and FeIII as the cause of oxidative stress, leading to damages 
that can potentially cause neurodegeneration in the brain.  The ability of CuIIAβ1–16 and 
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CuIIAβ1–20 to perform catechol- and phenol-oxidase-like chemistry has been recently 
proposed.63, 64  The suggested metal-centered redox catalysis involves two electron  
transfers from the CuII complex to the substrate for the oxidation of catechol to ortho-
quinone.  In the presence of O2 or H2O2, the continuation of oxidative chemistry is 
enhanced.63, 64  The ability of these CuIIAβ complexes to oxidize neurotransmitters, such 
as dopamine and serotonin, has been shown through in vitro studies,38 suggesting a 
possible mechanism for the oxidative stress.  Owing to the fact that oxidative stress is in 
this case metal-dependent chelation therapy has gained much interest in AD search.   
Two well known attributes of Qr in terms of antioxidant activity are metal 
chelation and free radical scavenging.  As a result, this natural metal chelator is a 
potential candidate for use as a therapeutic agent or a template for future drug design for 
the treatment of AD.  In fact, several studies have indicated the neuroprotective role of 
this ubiquitous natural product.45  The structure of Qr has three potential metal-binding 
sites, rendering it a very effective metal chelator.  In addition, the B ring of Qr has a 
catechol moiety, which may allow this flavonoid to potentially act as a suicide substrate.  
This, in turn, may prevent the depletion of catechol- and phenol-containing 
neurotransmitters, such as dopamine and serotonin, in the brain. 
The hypothesis was tested by checking the influence of Qr toward the metal-
centered oxidation of catechol by CuIIAβ1–20.  The catechol oxidation was followed by 
monitoring the red adduct formed between the oxidized product, o-quinone, and MBTH, 
an o-quinone-specific indicator, at 500 nm.  When different concentrations (0–153.6 μM) 
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of Qr was incubated with 3.0 μM CuIIAβ1–20, a sharp decrease in the oxidation activity 
toward 400.0 μM catechol was observed in a concentration dependent manner, and then 
followed by a less drastic decrease (Figure 2.4 inset).  From this observation, Qr can 
effectively inhibit the oxidation chemistry of CuIIAβ1–20 at submicromolar concentrations, 
and at roughly 10.0 μM Qr, the loss of 50% activity is observed.  A full inhibition study 
was performed in order to reveal the inhibition pattern (Figure 2.4).   
Different concentrations of catechol were incubated with 3.0 μM CuIIAβ1–20 at 
several concentrations of Qr in 100.0 mM HEPES at pH 7.0 and 25 °C.  At all 
concentrations of Qr, the data show an initial increase in catechol oxidation, followed by 
a saturation at higher substrate concentrations.  This pattern suggests a possible pre-
equilibrium kinetics, which is in agreement with previous studies.63, 64  The pre-
equilibrium kinetics (Eq. 1) can be described as follows:   
[Cu(II)-Amyloid-CA][Cu(II)-Amyloid] + [CA] [Cu(II)-Amyloid] + o-quinone
k1
k-1
kcat
 
where ]
[ ]
[CAK
CAV
M
Max
+=0ν  (1) and VMax are the initial and maximum velocity, respectively, 
and 
1
1
k
kk
K catM −
+=  is the virtual dissociation constant of the CuIIAβ1–20-CA complex.  
At high concentration of the substrate, the activities of Qr are similar, suggesting similar 
maximum velocity values, Vmax.  The dissociation constant, KM when substrate 
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concentration is ~0.5*Vmax, for the CuIIAβ1–20-CA complex increases with increasing Qr 
concentration.  These behaviors are typical to that of competitive inhibition.65   
In competitive inhibition, the substrate [CA] and the inhibitor [Qr] are considered 
mutually exclusive according to this relationship:   
[Cu(II)-Amyloid-CA][Cu(II)-Amyloid] + [CA] [Cu(II)-Amyloid] + o-quinone
KCA
kcat
+
[Qr]
[Cu(II)-Amyloid-Qr]
KI
 
The equation 2 below represents a competitive inhibition:   
[ ]
[ ] [ ]CA
K
QrK
CAV
I
CA +⎟⎟⎠
⎞
⎜⎜⎝
⎛ +
=
1
maxν (2), where KI is the inhibition constant and KCA is the 
dissociation constant of the CuIIAβ1–20-CA complex.  The observed behaviors in the data 
can be described accordingly.  The only difference between Eq. 1 and 2 is KM versus 
[ ]
⎟⎟⎠
⎞
⎜⎜⎝
⎛ +
I
CA K
QrK 1 , and in the absence of inhibitor, KCa = KM.  Thus, in competitive inhibition 
the Vmax values at all inhibitor concentrations are similar and changes are only seen in the 
apparent KM values.65  The data at each Qr concentration was fitted to Eq. 2 to obtain 
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individual KI values.  The fitted inhibition constant (the average of individual KI values) 
for the Qr inhibition of catechol oxidation by CuIIAβ1–20 is 4.26 μM. 
The data were also plotted and fitted linearly, as the Lineweaver-Burk plots (1/υ 
vs. 1/[catechol]) (Eq. 3).  The reciprocal form of the velocity equation for competitive 
inhibition is:   
[ ]
[ ] maxmax
1111
VCAK
Qr
V
K
I
M +⎟⎟⎠
⎞
⎜⎜⎝
⎛ +=ν  (3) 
[Qr
KV
K
V
Kslope
I
CAM ⎟⎟⎠
⎞
⎜⎜⎝
⎛+=
maxmax
] (4) 
where KI = –[Qr] when slope = 0 and KI is the inhibition constant which can be easily 
obtained from a secondary plot (Eq. 4).  The point of convergence from the fitted lines 
can also suggest the type of inhibition present.  The lines from the fits converge at the y-
axis, suggesting a competitive inhibition (Figure 2.5 left).65  This conclusion is in 
congruence with the above non-linear behaviors.  From a secondary plot of the fitted 
slopes versus Qr (inhibitor) concentrations, an inhibition constant, KI, of 4.24 μM, (KI = – 
x-intercept) is determined, which is in agreement with the value from the non-linear fit 
(Figure 2.5 right).  The observed competitive inhibition is in agreement with the 
inhibition of the di-CuII center protein tyrosinase (KI = 38.6 μM) by O2.  The inhibition of 
tyrosine by Qr was credited to the metal binding property of Qr.56, 57   
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Figure 2.4.  Quercetin inhibition of catechol oxidation by CuIIAβ1–20.  Different 
concentrations of catechol (0–3.2 mM) were incubated with 3.0 μM CuIIAβ1–20 with 
different concentrations of Qr (0–8.0 μM) in 100.0 mM HEPES pH 7.0 and 25°C.  The 
inset is the Dixon plot or direct titration of Qr, monitored with the activity. 
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Figure 2.5.  Lineweaver-Burk analysis of quercetin inhibition of catechol oxidation by 
CuIIAβ1–20 (left) and replot of the slope versus inhibitor concentrations (right).  The 
Lineweaver-Burk fitted lines intersect at x = 0, which is an indication of a competitive 
inhibition pattern.  The inhibition constant, KI, is equal to the negative of the x-intercept 
of the secondary plot of the slope from the plot on the right or a function of [Qr]. 
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  The mechanism of inhibition by Qr can be due to metal chelation or free radical 
scavenging.  In our recent publication, we have shown the inability of mannitol and 
DMSO, hydroxyl and superoxide free radical scavengers, respectively, to stop the 
oxidation chemistry.63  Thus, the inhibitory action may be from the metal chelation 
property of Qr.  Based on the observed competitive inhibition, it is possible that Qr binds 
to the CuII center and prevents the substrate from binding.  This may be proposed from 
the non-linear plots of the inhibition study, where the KM (approximately 0.5*Vmax), the 
binding or dissociation constant for the CuIIAβ1–20-catechol complex, increases as the Qr 
concentration is increased (Figure 2.4).  Qr may be competing against catechol in binding 
to the CuII center.  As a result, the binding between the catalyst and substrate is weakened 
as indicated by the increasing KM at higher Qr concentrations. 
Metal-binding studies of Qr have been previously done, using multiple physical 
techniques.51  Qr has three potential metal-binding sites:  β-keto-phenolate (4-carbonyl 
and 5-hydroxyl); α-keto-enolate (4-carbonyl and 3-hydroxyl); and catecholate (3'- and 4'-
hydroxyl) (Figure 2.3).  However, no consensus has been reached on the metal binding 
mode of Qr.51  Since the antioxidant activity of Qr may be due to metal-binding, it is 
important to determine which metal-binding site and how well this flavonoid can chelate 
the metal ion in solution.  Thus, the metal binding by Qr was studied with UV-Vis and 
NMR spectroscopy in DMSO.  Qr (20.0 μM) was slowly titrated with copper sulfate 
(CuSO4) in DMSO and monitored from 200–800 nm.  Triethylamine (TEA), was added 
as needed to ensure full deprotonation of all metal-binding sites.   
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The electronic spectrum of Qr in the absence of metal shows two absorptions at 
~280 and ~380 nm (Figure 2.6); they have been previously assigned to the benzoyl (A 
ring including the β-keto-phenolate moiety) and cinnamoyl (C ring including the α-keto-
enolate and catecholate moieties), respectively.51b, c  Upon addition of CuII, a new 
absorption appears at 450 nm, accompanied by a decrease in the absorption of free ligand 
at 380 nm.  This new absorption along with two isosbestic points at 325 and 410 nm 
indicates the formation of CuII-Qr complex (Figure 2.6).  The CuII-to-Qr stoichiometry 
has been proposed from 1:1 up to 2:3, depending on the phase (i.e.  solid vs. liquid) as 
well as solvent (i.e.  EtOH vs. aqueous).51  In this study, the plot of the molar absorptivity 
value at 450 nm versus the equivalents of CuII added shows a saturation approximately at 
1.2 equivalents of CuII in DMSO (Figure 2.6 inset).  Then, the plot of the molar 
absorptivity value at 450 nm against CuII concentration can be fitted to a 1:1 metal-to-
ligand binding quadratic equation to afford an affinity constant, KCu, of 1.06 × 106 M–1 
(Figure 2.6 inset).   
The preferred stoichiometry between CuII and Qr was determined using the Job 
method.  It is a continuous variation method that can suggest the optimum binding 
between a metal and a ligand or interaction between a catalyst and a substrate.61, 62  In the 
optical Job study, the concentrations of CuII and Qr were arrayed while keeping the 
overall concentration constant.  The molar absorptivity of the CuII-Qr complex at 450 nm 
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Figure 2.6.  Optical titration of CuII (0–2.0 equivalents) to Qr (20.0 μM) in DMSO.  An 
isosbestic point at 410 nm along with an increase in the absorption at 450 nm indicates 
the formation of CuII-Qr complex.  Fitting the absorbance values with respect to [CuII] 
affords an affinity constant, KCu, of 1.06 × 106 M–1 (the inset). 
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was plotted against the mole fraction of CuII ( [ ][ ] [ ]( )QrCuCuII
II
+ ) (Figure 2.7 inset).  The 
result shows an increase in the absorption of the complex with ΧCu(II) and reaches a 
maximum at ΧCu(II) = 0.5, followed by the decrease (Figure 2.7 inset).  The result can be 
fitted to a stoichiometry of 1:1 for the binding between CuII and Qr (Figure 2.7 inset). 
The slow electronic relaxation of CuII can broaden the NMR signals beyond detection, 
rendering it useless in the metal-binding study by means of NMR spectroscopy.  
However, the fast relaxing CoII has been effectively utilized as a paramagnetic NMR 
probe in studying the metal-coordination site of various systems.66  To ensure that CoII 
binds Qr in a similar way to CuII, the optical studies were repeated with CoII.  A gradual 
addition of CoII into 20.0 μM Qr was monitored with a spectrophotometer from 200–800 
nm.  Similar to the CuII binding study, a new absorption appears at 450 nm, accompanied 
by a corresponding decrease in the absorption at 380 nm.  The absorption at 450 nm and 
the two isosbestic points at 305 and 410 nm suggest the formation of the CoII-Qr complex 
in a single equilibrium (Figure 2.8).  The affinity constant KCo of 5.58 × 105 M–1 was 
determined by fitting the plot of molar absorptivity value of the complex versus CoII 
concentration (Figure 2.8 inset).  The stoichiometry of the bound species was further 
determined with the Job method.  Similar to the data from CuII binding study, a gradual 
increase in the absorption of the CoII-Qr complex (450 nm) with ΧCo(II) reaches a 
maximum at ΧCo(II) = 0.5, followed by a decrease (Figure 2.9 inset).  This suggests that a 
1:1 species is the preferred stoichiometry between  CoII and Qr under the experimental  
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Figure 2.7.  Optical Job plot of CuII (0–20.0 μM) binding by Qr (0–20.0 μM) in DMSO.  
The molar absorptivity values at 450 nm of the complex was plotted against the mole 
fraction with respect to the CuII concentration (the inset).  The data was fitted to a simple 
1:1 metal-to-ligand binding with the r2 value of 0.93. 
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Figure 2.8.  Optical titration of CoII (0–12.8 equivalents) to Qr (20.0 μM) in DMSO.  An 
isosbestic point at 405 nm along with an increase in the absorption at 450 nm indicates 
the formation of a CoII-Qr complex.  Fitting the absorbance values at 450 nm with respect 
to [CoII] affords an affinity constant KCo of 5.58 × 105 M–1 (the inset). 
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conditions herein.  Overall, Qr binds CuII and CoII similarly, and the decrease in the 
absorption at 380 nm for both studies suggests the possible involvement of α-keto-enolate 
or catecholate moiety (the cinnamoyl group) in chelating metal ion.51b, c 
To further elucidate the preferred binding site among the three possible moieties 
on Qr in solution, the optical CoII binding to 5-hydroxyflavone (5HF) and catechin (CN) 
were performed.  While the structure of 5HF only has the β-keto-phenolate moiety for 
metal binding, the only functional group available for chelating metal on CN is the  
catecholate moiety (Figure 2.3).  The electronic spectrum of free CN shows an absorption 
at approximately 285 nm.  Upon CoII addition to CN, a new absorption appears at 313 nm 
(an isosbestic point at 298 nm) with a corresponding minor decrease in the absorption at 
285 nm, indicating the complexation between CoII and CN (Figure 2.10 left).  Similarly, 
the increase in a new absorption at 410 nm (with an isosbestic point at 368 nm) coupled 
with the decrease in the absorption of free 5HF at 335 nm upon gradual addition of CoII 
marks the formation of a CoII-5HF complex (Figure 2.10 right).  The absorptions of the 
CoII-catecholate (313 nm) and -β-keto-phenolate (410 nm) complexes can be clearly 
distinguished from that of the CoII-Qr complex, which appears at 450 nm, indicating the 
CoII binding site cannot be the α-keto-phenolate and the catecholate site.  By default, the 
CoII binding site in Qr is α-keto-enolate.  However, the possibility of CoII-β-keto- 
phenolate binding cannot be completely ruled out since the absorptions of the complexes 
are close.  The metal-binding site was further confirmed by means of NMR spectroscopy.
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Figure 2.9.  Optical Job plot of CoII (0–20.0 μM) binding to Qr (0–20.0 μM) in DMSO.  
The plot of the molar absorptivity values at 450 nm versus the mole fraction with respect 
to the mole fraction of CoII fits well to a 1:1 species with the r2 = 0.95 (the inset). 
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Figure 2.10.  Optical CoII titration of catechin (left) and 5-hydroxyflavone (right).  The 
new absorption at 313 nm for catechin and 410 nm for 5-hydroxyflavone along with their 
corresponding isosbestic points at 298 and 368 nm, respectively, indicates the formation 
of CoII-ligand complexes. 
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NMR is a powerful spectroscopic technique for studying the coordination 
environment of paramagnetic metal ions, such as CoII, FeII, and NiII as well as some 
lanthanideIII ions, in both simple complexes and metallo-proteins.66  Because of the 
overwhelming electron magnetic moment of the unpaired electron(s) in the paramagnetic 
systems (658 times that of the proton), the coordination environment is very sensitive to 
changes due to electron-nuclear hyperfine interaction.  As a result, metal ions such as CoII 
and YbIII have been commonly utilized as paramagnetic NMR probes for studying the 
metal coordination environments in ZnII- and CaII-containing metalloproteins, 
respectively, upon replacing the native metal ions in the proteins with CoII and YbIII 
ions.66  The same electron-nuclear hyperfine interaction is responsible for shifting the 
signals of the coordinated ligand and outside the typical diamagnetic spectral region (0–
15 ppm).  In addition, the fast electronic relaxation of these paramagnetic agents can 
enhance nuclear relaxation; thus, the relaxation time of the signals close to the metal ion 
is considerably shortened.  The slow electronic relaxation of CuII (10–8–10–11s) can 
reduce the nuclear relaxation time and can lead to broadening of the signals beyond 
detection.  The fast relaxing CoII (10–11–10–13s), however, can afford relatively sharp 
shifted signals.66  Thus, CoII was used in place of CuII for the determination of the metal 
binding site on Qr.  A complete assignment of the 1H NMR spectrum of the CoII-Qr 
complex is accomplished by the use of 1D and 2D saturation transfer NMR techniques, 62, 
67  owing to the presence of exchange between the metal-bound and metal-free Qr 
according to the equilibrium, M + Qr  M–Qr.   
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The 1H NMR spectrum of CoII-Qr acquired in d6-DMSO displays 8 
paramagnetically shifted signals (out of 10 protons) within the spectral region of 60 to –
80 ppm (Figure 2.11).  TEA was added as needed to ensure full deprotonation of all three 
metal-binding sites on Qr.  The proton spectrum in Fig. 2.11 was acquired with the 
superWEFT (modified Water Eliminated Fourier Transform) (τ1-180°-τ2-90°-FID),68 a 
solvent suppression technique for paramagnetic systems that selectively suppresses the 
slowly relaxing diamagnetic signals.  As a result, the diamagnetic signals appeared 
distorted.     
An exchanging system allows the use of 2D saturation transfer experiment, EXSY 
(EXchanged SpectroscopY), for the assignment of paramagnetic signals once the 
diamagnetic free ligand signals are fully assigned.67  From the EXSY spectrum, 5 out of 8 
shifted paramagnetic signals can be connected to their corresponding diamagnetic 
counterparts.  The shifted signals at 17.0 and 16.3 ppm of the CoII-Qr complex are in 
exchange with the signals of the 3'-OH and 4'-OH protons, respectively, of the catechol 
moiety of free Qr (3' and 4' cross peaks Figure 2.12).  This assignment clearly shows that 
the catecholate moiety on Qr does not involve in metal binding, otherwise the 3 and 4 
protons should not be detected since they deprotonate upon metal binding.  This 
conclusion is in agreement with the finding from optical studies.  The remaining three 
signals are correlated with 6-H, 8-H, and 5'-H protons (Fig. 2.12 and Table 2.1).   
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Figure 2.11.  1D NMR spectrum of Co(II)-(25.0 mM) Qr-TEA in a 1:5:1.5 ratio in d6–
DMSO.  The spectrum was acquired with the spectral width of 110k (–100 to 100 ppm) 
on the Varian INOVA500 using superWEFT (Water Eliminated Fourier Transform)68 
technique to selectively observe the fast-relaxing paramagnetically shifted signals over 
the diamagnetic ones.  The signal intensities are quite different owing to their very 
different relaxation times which result in signal saturation to different extents.  The 
inverted signals are due to “diamagnetic protons” far away from the paramagnetic metal 
center, which do not relax to gain positive intensity after the 180º pulse and the short 
delay. 
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The broadness of the three furthest shifted signals (56.4, 49.8, and –75.1 ppm) did 
not allow the assignment by 2D EXSY experiment.  However, they can be assigned with 
1D saturation transfer technique.  The irradiation of the most upfield shifted signal at –
75.1 ppm reveals saturation transfer to the signal at 12.5 ppm corresponding to 5-H of the 
hydroxyl proton of the β-keto-phenolate moiety on the structure of Qr.  Furthermore, the 
protons of the two most downfield shifted signals at 56.4 and 49.8 ppm are in exchange 
with 2'-H and 6'-H protons, respectively (Figure 2.13).  The solvent exchangeable 
hydroxyl OH signals can be easily identified with the addition of a few drops of D2O to 
the d6-DMSO solution.  The OH signals are identified as the signals at 17.0, 16.3, and –
75.1 ppm, correlating to 3'-H, 4'-H, and 5-H.  They are in agreement with the assignments 
by 2D EXSY and 1D saturation transfer experiments.   
After all the paramagnetic signals have been assigned, the two proton signals left 
unaccounted for are the hydroxyl protons at 7-H and 3-H.  The former is a free-standing 
hydroxyl group and unlikely to be the preferred metal binding site.  The latter, however, 
is the hydroxyl proton for the α-keto-enolate moiety, and the absence of a paramagnetic 
counterpart may indicate the deprotonation of the enol group and binding of the metal 
ion.  On the other hand, the shifted signal for 5-H suggests that the β-keto-phenolate site 
is still protonated.  The protons closest to the metal ion will be most affected by the 
electron-nuclear interaction, and they are expected to have larger paramagnetic shifts as 
well as shorter relaxation times.  With the conclusion above that Qr binds CoII at the α-
keto-enolate moiety, the protons in the closest proximity are the 5-H on the β-keto- 
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Figure 2.12.  The 2D 1H EXSY spectrum of the 1:1:0.1 CoII-(31.0 mM) Qr-TEA 
complex in d6-DMSO.  The data was acquired with the mixing time of 90 ms.  The 
paramagnetic signals (marked with asterisks) of the complex are correlated to their 
diamagnetic counterparts, and the numbers next to the crosspeaks represent the protons 
according to Figure 2.3.
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 Figure 2.13.  1D saturation-transfer results for the CoII-Qr complex.  The difference 
spectra from the 1D 1H saturation transfer experiments for the three farthest shifted 
signals, –75.1, 49.8, and 56.4 ppm show connections with their corresponding 
diamagnetic protons (7.5, 7.6, and 12.5 ppm, bottom to top) of the 1:1 CoII-Qr complex. 
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phenolate site and both 6'-H and 2'-H, since the single bond allows the rotation of the B 
ring (Figure 2.3).  Thus, the 5-H, 2'-H, and 6'-H protons are expected to have the largest 
chemical shifts, –75.1, 49.8, and 56.4 ppm, respectively, in comparison to the remaining 
shifted signals.  In addition, T1 relaxation times for all shifted signals were determined 
with the standard inversion recovery method (τ1–180–τ2–90) and are reported in Table 1.  
As expected, 5-H, the closest proton to the CoII ion, has the lowest T1 value (4.0 ms) 
among all, followed by the 6'-H (5.4 ms) and 2'-H (6.2 ms) signals.  From the combined 
results, the metal binding on Qr can be unambiguously assigned to the α-keto-enolate 
moiety. 
Physiological studies have shown that soluble Aβ peptides of the sequence 1–40, 
1–42, and 25–35 can increase the intracellular CaII concentration in hippocampus, 
deteriorating learning ability and memory.33  Both the soluble and aggregated forms of 
the amyloid-β peptides can span lipid membrane which creates channels with poor ion 
selectivity35 and can cause membrane depolarization and impair Na+/K+-ATPase which 
leads to an increase in CaII influx.36,37  The rise in the CaII level can defect neurons and 
synapses, deter long-term potentiation in certain brain regions, and lead to impairments in 
learning and memory.32–37   
As shown earlier, Qr is a potent inhibitor (KI = 4.24 μM) against the catechol 
oxidation chemistry of CuIIAβ1–20.  A possible mechanism of inhibition is chelation of the 
CuII center by Qr; this prevents the substrate from binding to the CuII center. 
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1H Position σdia (ppm) σpara (ppm) T1 (ms)    
6'-H 7.5 56.4 5.4 
2'-H 7.6 49.8 6.2 
5'-H 6.9 19.1 89 
3'-OH 9.3 17.0 213 
4'-OH 9.6 16.3 408 
8-H 6.4 13.0 158 
6-H 6.2 –4.3 134 
5-OH 12.5 –75.1 4.0 
 
Table 2.1.  Full assignment of the 1H NMR spectrum of the 1:1:0.1 CoII-(31.0 mM) Qr-
TEA complex from 1D saturation transfer and 2D EXSY experiments and their 
corresponding T1 relaxation times. 
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Alternatively, Qr can act as a suicide substrate and can be oxidized by the CuIIAβ1–20 
complex, competing with other physiologically important substrates.  There are three 
possible sites on Qr for interacting with the metal ion, and the mode of binding can 
suggest the possible mechanism of inhibition.  For example, if the catecholate moiety is 
the binding site, Qr is potentially oxidized since CuIIAβ1–20 has been shown to have both 
catechol- and phenol-oxidase activity.63, 64  The metal binding site of Qr has been 
determined to be at the α-keto-enolate moiety by means of optical and NMR 
spectroscopy discussed above.  Thus, the antioxidative mechanism of Qr is possibly 
through chelation of the metal center.  This finding is important since Qr is a naturally 
occurring antioxidant which may be applicable as a therapeutic agent against the redox 
metal-dependent oxidative stress in the pathology of AD. 
Since Qr is a good metal chelator,51 it may indiscriminately bind CaII at the same 
site and blocks its binding to the metal in CuIIAβ1–20.  As a result, the increased 
intracellular CaII concentration may reduce the antioxidative effect of Qr in the brain.  To 
gain further information about the metal-binding versatility of Qr, the binding of the 
biologically significant CaII to Qr was investigated.  A new absorption at 450 nm and an 
isosbestic point at 405 nm (Fig. 2.14) are analogous to the transition metal complexes of 
Qr (Figs. 2.6 and 2.8), confirming the formation of CaII-Qr complex.  Fitting of the molar 
absorptivity value (at 405 nm) as a function of CaII concentration gives a smaller affinity 
constant KCa of 530 M–1.  
 79
Wavelength (nm)
300 400 500 600 700 800
ε (
M
-1
cm
-1
)
0
5000
10000
15000
20000
25000
30000
[Ca(II)]/[Qr]
0 2e+2 4e+2 6e+2 8e+2 1e+3
ΔA
bs
45
0
0.00
0.05
0.10
0.15
0.20
F
igure 2.14.  Optical titration of CaII (0–819.2 equivalents) to Qr (20.0 μM) in DMSO.  
An isosbestic point at 405 nm along with an increase in the absorption at 450 nm 
indicates the formation of CaII-Qr complex.  Fitting the absorbance values versus [CaII] 
affords an affinity constant, KCa, of 5.35 × 102 M–1 (the inset). 
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The influence of CaII on the antioxidative activity of Qr was probed with respect 
to catechol oxidation.  Several concentrations of CaII (0–160 mM) were incubated with 
3.0 μM CuIIAβ1–20 and a fixed concentration of catechol in the presence of 4.0 μM Qr in 
100 mM HEPES at pH 7.0 and 25 °C.  The catechol oxidation gradually increases with 
increasing CaII concentrations and eventually reaches a plateau at high millimolar (mM) 
concentrations of CaII (Figure 2.15 inset).  The saturation profile potentially indicates that 
the presence of CaII is some how promoting the substrate’s ability to interact with the 
redox CuII center, since CaII is a redox-inert metal.  It is possible that CaII is interfering 
with the CuII center chelated by Qr.  Even though the affinity of Qr toward CaII is not as 
strong as that of CuII, the binding and removing of Qr from the CuII center may occur in 
the presence of high concentrations of CaII.  This is evident in the requirement of mM 
concentration in order to clearly see the effect.   
The effect of CaII was further investigated with kinetics.  Different concentrations 
of catechol (0–3.2 mM) were incubated with 4.0 μM Qr (KI concentration) and 3.0 μM 
CuIIAβ1–20 with different concentrations of CaII (0–80.0 mM) in 100.0 mM HEPES pH 
7.0 and 25 °C.  At all concentrations of CaII, the data show an initial increase in catechol 
oxidation, followed by a saturation at higher substrate concentrations (Figure 2.15).  This 
pattern suggests a possible pre-equilibrium kinetics, which indicates CaII binding to Qr.  
A rate law (Eq. 5) is derived according to the following relationship: 
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where [I]0 = experimental [Qr], [Ca]0 = experimental [CaII], KI = Qr inhibition constant, 
KCatechol = intrinsic (in the absence of Qr and Ca ) dissociation constant of catechol, and 
KCal = dissociation constant for Ca .  The results are fitted to Eq. 5 to afford KCal = 0.263 
M.  This large dissociation constant for Ca  is consistent with the small affinity constant 
observed from the optical titration, which also suggests the influence of Ca  on Qr 
inhibition of catechol oxidation chemistry by Cu Aβ is the result of binding to Qr. 
Since the effect of CaII toward Qr inhibition of catechol oxidation by CuIIAβ1–20 is 
potentially due to binding to Qr and removing of Qr from the CuII center for oxidation, it 
is essential to know how Qr binds Ca  in order to make a correlation between the 
structure and observed activity.  Thus, the Ca  binding mode of Qr was elucidated by 
means of NMR spectroscopy.  Since Ca  is spectroscopically inert, the lanthanide Yb   
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Figure 2.15.  Calcium influence on quercetin inhibition of catechol oxidation by 
CuIIAβ1–20.  Different concentrations of catechol (0–3.2 mM) were incubated with 4.0 μM 
Qr at KI concentration and 3 μM CuIIAβ1–20 with different concentrations of CaII (0–80.0 
mM) in 100.0 mM HEPES pH 7.0 and 25 °C.  The inset is the direct titration of CaII in 
the presence of the inhibitor, Qr, monitored with the activity.  
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was used as a paramagnetic NMR probe.  The lanthanides have similar radii and ligand 
binding preferences as CaII and thus are good CaII substitutes in biological systems.69   
Similar to the CoII binding study, the 1HNMR spectrum of the YbIII-Qr complex shows 
the exchange between the free and metal-bound form of Qr.  As a result, 1D and 2D 
saturation transfer experiments, such as 1D NOE difference and 2D EXSY, were used in 
the assignment of paramagnetically shifted signals.  The 1H NMR spectrum displays 9 
shifted signals within the range of 20 to –40 ppm (marked, Figure 2.16).  Unlike the CoII-
Qr spectrum, some signals of the YbIII-Qr complex appear within the diamagnetic 
spectral region (0–15 ppm).  This is due to the difference between the transition and 
lanthanide metal ions in their electron-nuclear interaction.  While the through-bond 
interaction mainly occurs in the transition metal complexes, only the through-space or 
dipolar interaction can take place in the lanthanide complexes, since the f orbitals in the 
lanthanides are shielded and do not overlap with the ligand orbitals.  Furthermore, the 
dipolar interaction only occurs in the presence of magnetic anisotropy, and the direction 
and magnitude of magnetic anisotropy determine the direction and magnitude of the 
dipolar shift.66   
From the EXSY spectra, 8 shifted signals of the YbIII-Qr complex can be assigned 
to their diamagnetic counterparts of metal-free Qr (Figures 2.17 and 2.18).  Half of these 
signals are determined to be solvent-exchangeable OH protons based on the 
disappearance of signals upon D2O addition.  Among them, the signals at 19.2, 4.1, and  
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Figure 2.16.  1D NMR spectrum of Yb(III)-Qr-TEA in a 1:1:0.7 ratio in d6–DMSO.  The 
spectrum was acquired with the spectral width of –100 to 100 ppm on the Varian 
INOVA500 using superWEFT technique. 
 85
2.1 ppm are exchanging with the diamagnetic signals at 12.5, 9.6, and 9.3 ppm, 
corresponding to 5-H, 4'-H, and 3'-H on the structure of Qr (Figure 2.3).  The one 
remaining signal at 6 ppm was assigned to 6-H with the 1D saturation transfer 
experiment.  Similar to the results from the CoII binding study, the protons at the β-keto-
phenolate (5-H) and catecholate (4'-H and 3'-H) sites are present, which indicate their 
noninvolvement in metal binding.  On the opposite note, the absence of 3-H signal along 
with short T1 relaxation times of the nearby protons (5-H, 6'-H, and 2'-H) clearly indicate 
the α-keto-enolate site to be the YbIII binding site.  The exchange correlations along with 
the corresponding T1 values are summarized in Table 2.2. 
Based on the YbIII binding study, Qr may potentially bind CaII at the same site as 
CuII and CoII, which is at the α-keto-enolate moiety.  This may explain the effect of CaII 
toward the Qr inhition of catechol oxidation by CuIIAβ1–20.  At sufficiently high 
concentration of CaII, it can compete with CuII in binding to Qr, since Qr binds both CaII 
and CuII at the same site.  As a result, the CuII center of the CuIIAβ1–20 complex is made 
available for binding and oxidation of catechol.  In order to confirm this hypothesis, the 
influence of YbIII on the Qr inhibition was determined with optical and kinetic studies.  
While the optical study ensures the similarity between CaII and YbIII binding to Qr, the 
kinetic study will help to determine if the CaII interference in the Qr inhibition is the 
result of its binding to Qr. 
Consistent with the transition metals and CaII binding studies, a new absorption 
appears at approximately 440 nm upon addition of YbIII to Qr (Figure 2.19).  A  
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Figure 2.17.  The 2D 1H EXSY spectrum of the 1:1:0.7 YbIII-Qr-TEA complex in d6-
DMSO.  The data was acquired with mixing time of 8.3 ms.  The protons shifted the 
farthest with respect to the diamagnetic envelope, indicating their close proximity to the 
metal center. 
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Figure 2.18.  The 2D 1H EXSY spectrum of the expanded region of ~12 to –4 ppm for 
Fig. 2.17 of the 1:1:0.7 YbIII-Qr-TEA complex in d6-DMSO.  The data was acquired with 
a mixing time of 8.3 ms.  The presence of a crosspeak for 3'-OH eliminates the catechol 
moiety from being a possible metal-binding site.
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 1H Position σdia (ppm) σpara (ppm) T1 (ms)    
5-OH 12.5 19.2 8.3 
7-H 10.9 8.8 832 
6-H 6.2 6.0 420 
3'-OH 9.3 2.1 638 
8-H 6.4 –1.1 554 
5'-H 6.9 –3.5 339 
2'-H 7.8 –24.6 32.1 
6'-H 7.7 –32.2 24.3 
 
Table 2.2.  Full assignment of the 1H NMR spectrum of the 1:1:0.7 YbIII-Qr-TEA 
complex from 1D saturation transfer and 2D EXSY experiments and their corresponding 
T1 relaxation times. 
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corresponding decrease in the absorption of the free Qr in 380 nm is observed along with 
the isosbestic point at roughly 400 nm, which indicates the formation of YbIII-Qr 
complex.  Fitting the molar absorptivity at 440 nm versus YbIII concentration to a simple 
1:1 binding pattern affords an affinity constant KYb = 5.60 × 105 M–1 (Figure 2.19, inset).  
The stoichiometry of the binding between YbIII and Qr was further determined with the 
Job method as described above.  The plot of the molar absorptivity values at 440 nm 
versus the mole fraction of YbIII shows a maximum absorption intensity at ΧYb(III) = 0.5, 
which indicates the preferred stoichiometry to be 1:1 (Figure 2.20, inset). 
The influence of YbIII on the antioxidative activity of Qr was further investigated 
with respect to catechol oxidation.  Several concentrations of YbIII (0–600.0 μM) were 
incubated with 3.0 μM CuIIAβ1–20 and a fixed concentration of catechol in the presence of 
4.0 μM Qr in 100.0 mM HEPES at pH 7.0 and 25 °C.  An increase in catechol oxidation 
was observed with increasing YbIII concentration and reaches a plateau at high 
micromolar (μM) concentration.   
The effect of YbIII was further investigated with kinetics.  Different 
concentrations of catechol (0–3.2 mM) were incubated with 4.0 μM Qr (KI concentration) 
and 3.0 μM CuIIAβ1–20 with different concentrations of YbIII (0–600.0 μM) in 100.0 mM 
HEPES pH 7.0 and 25 °C.  At all concentrations of YbIII, the data show an initial increase 
in catechol oxidation, followed by a saturation at higher substrate concentrations (Figure 
2.21).  This pattern suggests a possible pre-equilibrium kinetics, which indicates YbIII 
binding to Qr.  A rate law (Eq. 6) is derived according to the following relationship: 
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Figure 2.19.  Optical titration of YbIII (0–6.4 equivalents) to Qr (20.0 μM) in DMSO.  An 
isosbestic point at ~400 nm along with an increase in the absorption at 440 nm indicates 
the formation of YbIII-Qr complex.  Fitting the molar absorptivity values with respect to 
the added YbIII equivalent affords an affinity constant, KYb, of 5.60 × 105 M–1 (the inset).
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where [I]0 = experimental [Qr], [YbIII]0 = experimental [YbIII], KI = Qr inhibition 
constant, KCatechol = intrinsic (in the absence of Qr and Yb ) dissociation constant of 
catechol, and KY = dissociation constant for Yb .  The results are fitted to Eq. 6 to afford 
KY = 4.85 × 10  M.  Compared to Ca , a smaller dissociation constant for Yb  is 
expected since its affinity toward Qr is approximately 1000 times higher than that of CaII 
based on the affinity constants obtained from the optical titration experiments. 
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Figure 2.20.  Optical Job plot of YbIII (0–20.0 μM) binding to Qr (0–20.0 μM) in DMSO.  
The plot of the absorbance at 440 nm versus the mole fraction of YbIII shows a maximum 
absorption intensity at ΧYb(III) = 0.5, which indicates the preferred stoichiometry to be 1:1 
(the inset). 
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Figure 2.21.  Ytterbium influence on quercetin inhibition of catechol oxidation by 
CuIIAβ1–20.  Different concentrations of catechol (0–5.0 mM) were incubated with 4.0 μM 
Qr (KI concentration) and 3.0 μM CuIIAβ1–20 with different concentrations of YbIII (0–
600.0 μM) in 100.0 mM HEPES pH 7.0 and 25°C.  The inset is the direct titration of YbIII 
in the presence of the inhibitor, Qr, monitored with the activity.  
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2.4 Conclusions 
 It is originally thought that the aggregation of Aβ peptide is the cause of 
neurodegeneration in the pathology of Alzheimer’s disease.15  However, there is 
inconsistency in the amount of plaque present and the severity of neurodegeneration.16  
Furthermore, the presence of high concentration of redox-active metal ions such as CuII 
and FeIII in the plaques11 along with oxidized biological molecules17 indicates that the 
metal dependent oxidative stress may be a culprit of neuronal damages in the brain.  As a 
result, the metal chelation therapy has become a center of attention.  A good metal 
chelator such as clioquinol has been proposed.39, 41  However, the testing of this drug has 
been stopped at the Phase II clinical trials due to its intrinsic toxicities.40–44   
Recently, naturally occurring flavonoids have gained the interests of researchers 
due to their biological properties.47  One of the most studied among them is Qr.  Qr is 
well known for its free radical scavenging and metal chelating abilities.50, 51  We have 
recently shown the ability of short N-terminal Aβ fragments (Aβ1–16 and Aβ1–20, which 
contains the metal binding domain) to perform catechol- and phenol-oxidase-like 
chemistry in the presence of CuII.63, 64  In this study, the antioxidant ability of Qr toward 
the observed oxidation chemistry is determined.  Qr can potentially serve two purposes.  
It can be a metal chelator (block the CuII center and prevent the substrate from binding) 
or a suicide substrate (the C ring contains a catechol moiety, which can be oxidized).  
Based on kinetic studies, Qr has been determined to competitively inhibit catechol 
oxidation by CuIIAβ with a KI of 4.24 μM.  Qr has three possible metal binding sites:  β-
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keto-phenolate, α-keto-enolate, and catecholate moiety.  The site of binding may suggest 
the mechanism of inhibition.  For example, if the metal is bound through the catecholate 
moiety, Qr is potentially oxidized by CuIIAβ, acting as a suicide substrate.  Thus, the 
metal binding studies were performed by means of optical and NMR spectroscopy.  
According to NMR results, the metal binding site can be unambiguously assigned to the 
α-keto-enolate moiety, suggesting that the mechanism of inhibition by Qr may be due to 
CuII center chelation.  A recent study showing tyrosinase inhibition by Qr supports this 
conclusion.57  
The Aβ peptide has been shown to cause a disruption in CaII homeostasis in AD, 
leading to the rise in intracellular CaII concentration.  Memory loss and cognitive 
impairments have been associated with an increase in CaII level.32–37  Since Qr can bind 
metal indiscriminately, the presence of CaII may interfere with its antioxidant ability, or 
on the other hand, the free CaII can be chelated by Qr which may decrease the damage 
caused by the extra free CaII.  As expected, the recovery of catechol oxidation by CuIIAβ 
was observed in the presence of high concentration of CaII.  The fact that the interference 
is due to CaII binding was shown by using YbIII as a spectroscopic probe (for 
spectroscopically inert CaII)  in optical and NMR studies.  Once again, the NMR results 
showed that Qr binds YbIII at the α-keto-enolate site.  This indicates that CaII binds Qr at 
the same site as CuII and thus releasing the CuII center for catechol oxidation.  These 
findings suggest that Qr may have dual protective roles in AD, preventing both the metal-
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centered oxidative stress by binding to the metal in CuIIAβ as well as CaII-induced 
memory and cognitive impairments by chelating CaII. 
Since Qr-containing fruits and vegetables make up a large part of our daily diets, 
this compound is relatively safe.47  Thus, Qr may be potentially used as a therapeutic 
agent toward AD.   However, one main concern for the flavonoids is their bioavailability, 
especially for Qr.  The hydrophobic nature of the polyphenolic structures greatly reduces 
its absorbability into the body.  Furthermore, metabolic processes can potentially change 
or modify the chemical structure(s), leading to the reduction or loss of function.70  
Another possibility that may contribute to this discrepancy is the inability of flavonoids 
to be at the places when they are needed, which includes being presence when they are 
not needed (e.g.  when ROS homeostasis is well maintained) and possible interaction 
with biomolecules (e.g.  hydrogen bonding through the hydroxyl group).71  As a result, 
the efficacies of naturally occurring antioxidants in vitro cannot be directly translated to 
the situations in vivo.  Thus, further in vivo studies in animal models are needed.  
Nonetheless, Qr may be a good starting point, serving as a template for future drug 
design. 
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CHAPTER 3 
 
 
ELUCIDATION OF THE IN VITRO OXIDATION CHEMISTRY OF 
COPPER(II)–BACITRACIN COMPLEX 
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3.1 Bacitracin 
Bacitracin (Bc) is an antibiotic peptide, isolated from Bacillus subtilis and B. 
licheniformis.1, 2  It was first isolated from an open wound of a young girl named 
Margaret Tracey.1  This antibiotic has come to be termed bacitracin.  It is active 
primarily against Gram-positive bacteria, including Staphylococcus, Streptococcus, and 
Clostridium difficile.3  In addition to its worldwide use in animal feed as a preventive 
drug for livestock,4 Bc makes up one of the ingredients in the commonly used topical 
triple antibiotic ointments, Neosporin® and Polysporin®, along with polymyxin B and 
neomycin since 1956.5  The three antibiotics have been suggested to work 
synergistically.  This may be one of the reasons for the rare occurrences of bacterial 
resistance, despite more than 50 years of over-the-counter usage.6  In addition, bacitra
has other well known functions, such as an inhibitor of disulfide isomerase
cin 
s 
regation.8   
7 as well a
platelet and multiple agonist agg
Although it is relatively safe for oral intake owing to the low absorption by the 
gastrointestinal tract, Bc can cause nephrotoxicity when given systemically.3, 5  The 
minute intestinal absorption has been previously shown in animal studies.9  It is generally 
safe for use in topical applications, but a growing concern in the topical usage of 
bacitracin is the increasing reports of allergic contact dermititis.10  A recent publication 
suggested this to be the result of improper or over usage of the drug (i.e.  application on 
all surgical wounds in hospitals and on fresh tattoo wounds).10b  The same study proposed 
white petrolatum to be used as an alternative for cleaning surgical wounds. 10b  
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Furthermore, bacitracin is one of the world’s massively produced and used food additives 
for farm animals it is until recently banned in European countries, which is an act of 
precaution against bacterial resistance.11  Up to 60% resistance by bacteria has been 
proposed,12 but a full resistance to the drug has not been reported over 5 decades of 
application.  Thus, relatively speaking bacitracin resistance still is a rare occurrence, and 
this is possibly due to its unique structure.2 
 
3.1.1 Structure of Bacitracin 
Bacitracin is synthesized non-ribosomally by bacitracin synthetase ABC, a multi-
enzyme complex consisted of BacA (598 kDa), BacB (297 kDa), and BacC (723 kDa).  
Each synthetase is responsible for the incorporation as well as chemical modification of 
different parts of the full-length peptide.13, 14  This peptide is produced as a mixture of 
closely related peptides, possibly as many as 50 variants.15  Among the congeners, 
bacitracin A1 (BcA) is the major component with the most potent antibiotic activity.16, 17  
Combined bacitracin A and B components are accountable for >90% of the biological 
activity although BcA2 has low activity.18  Bacitracin F is biologically inactive and has 
been proposed to be the cause of nephrotoxicity.  It is the oxidized product of BcA19 that 
can act as a vasoconstrictor toward kidneys.20   
Bacitracin was initially isolated using counter-current distribution technique,21 
and the structure was determined by NMR.22  Several structures were proposed, but the 
structure was not fully characterized until the early 1990’s by means of modern 2D NMR 
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techniques.23  The congeners can also be purified with reverse-phase HPLC and 
characterized with mass spectrometry and NMR spectroscopy. 24  The structure of BcA 
consists of a thiazoline ring formed by the condensation reaction between the carboxylate 
of Ile-1 and the –NH2 and the –SH groups of Cys-2.  It is a dodecapeptide, containing 
four D-amino acids, with a unique cyclic heptapeptide structure formed via an amide 
linkage between the side chain of Lys-6 and the C-terminus of Asn-12.23  In the 
characterized structure of Bc, the N-terminal end folds over the cyclic heptapeptide, 
placing the thiazoline ring, Glu-4, and His-10 in proximity.23  It has been suggested that 
these unusual structural features may prevent this peptide from being degraded by 
proteases.25  Structures of bacitracin congeners are displayed in Figure 3.1. 
 
3.1.2 Metal-Binding and Antibacterial Mechanism 
Bacitracin requires ZnII for its antibacterial activity26 and has been shown to bind 
several divalent metal ions, including CoII, NiII, and CuII, in a 1:1 stoichiometry. 27, 28  A 
previously proposed antibacterial mechanism of bacitracin involves the inhibition of 
peptidoglycan cell wall synthesis.  At the final step of the synthesis, the uridine 
diphosphate sugar molecule is transported to the cell wall by a lipid carrier known as C55-
isoprenyl pyrophosphate.29  After the incorporation of the disaccharide into the 
peptidoglycan layer, the lipid carrier is dephosphorylated to its monophosphate form in 
order to bind another sugar molecule.  The metalII-Bc complex inhibits the cell wall  
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 Figure 3.1..  Structures of bacitracin congeners (adopted from ref. 2).  Bacitracin is a 
dodecapeptide, containing four D-amino acids, with a unique cyclic heptapeptide 
structure formed via an amide linkage between the side chain of Lys-6 and the C-
terminus of Asn-12.  In BcA, the two N-terminal amino acids form a thiazoline ring by 
the condensation reaction between the carboxylate of Ile-1 and the –NH2 and the –SH 
groups of Cys-2. 
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synthesis by binding to the lipid carrier with high affinity (Kf = 1.05 × 106 M–1).30  Thus, 
metal coordination is an essential part of its biological activity.   
Metal binding of Bc have been studied by means of multiple techniques, 
including proton release titration, ORD, EPR, EXAFS, 1H NMR, and UV-Vis 
spectroscopy.28, 30, 31  One of the earlier studies proposed that the metal binding site is 
consisted of His-10 nitrogen, thiazoline ring (nitrogen or sulfur), and the amino group of 
Ile-1, based on a proton release titration.31b  Nonetheless, later studies did not suggest the 
involvement of Ile-1 group.  Another metal binding study with CuII and MnII suggested 
the binding through the imidazole ring of His-10, and the carbonyl group of acidic amino 
acid residues such as Asp and Glu according to 13C NMR results.31d  EPR28 and 
EXAFS31f studies showed metal binding through thiazoline ring, Glu-4, and His-10 but 
disagreed on the fourth ligand, Asp-11 and Ile-1-NH2 for EPR and EXAFS study, 
respectively. 
Finally, the metal binding site of Bc was unambiguously assigned by the use of 
CoII as a paramagnetic NMR probe.24  The suggested metal-binding ligands are the 
thiazoline ring nitrogen, the Nε nitrogen of His-10, and the carboxylate side chain of D-
Glu-4.24  Furthermore, the study suggested a correlation between the structure and 
function of bacitracin.  According to the authors, both BcA2 and BcF cannot effectively 
bind the metal ion to create a proper binding site for the lipid carrier.  Although Ile-1 is 
not involved in metal binding, it is important in creating a correct environment as seen in 
the inability of BcA2 (D-allo-Ile-1 versus L-Ile-1 of BacA1 at the N-terminus) to bind the 
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metal properly.  Likewise, BcF, having an oxidized thiazole ring instead of a thiazoline 
ring at the N-terminus, is only able to bind the metal ion weakly through the imidazole 
group of His-10.  In addition, no metal binding by D-Glu-4 was observed in both 
congeners.   
The structure of a metal-bound bacitracin was generated based on the T1 
relaxation results with a molecular modeling program.24  According to the proposed 
structure, the four N-terminal amino acid residues fold back onto the His-10-bound metal 
ion to complete the tridentate coordination sphere.  The structure also suggested the 
presence of a hydrophobic pocket (Ile-5, Phe-9, and Ile-10 are in close proximity).  This 
hydrophobic binding site was proposed to play an important role in lipid pyrophosphate 
binding, aided by the stabilization effect of Ile-1-NH3+ through H-bonding.  As a result, 
inability of binding metal correlates to the biological activity of Bac congeners. 24, 2 
Pyrophosphate and its several derivatives were found to bind to CoII-bacitracin to 
form kinetically inert ternary complexes by means of NMR spectroscopy.2b  The study 
suggested the pyrophosphate moiety to be the minimum necessity for binding to the 
metallo-bacitracin complex, since sodium phosphate was shown only to bind very 
weakly.2b  The ability of the metalII-Bc complex (not free Bc) to bind pyrophosphate may 
suggest a potential interaction with the phospho-group on DNA.  Thus, in the presence of 
a redox-active metal such as CuII, bacitracin may bind and perform an oxidative damage 
of DNA.  This hypothesis is supported by the CuII-dependent oxidation chemistry by 
metal-binding short peptides (e.g.  the amyloid-β peptides in the brain of the patients with 
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AD, Aβ1–16 and Aβ1–20) has been previously proposed.32, 33  In this study described 
herein, the catechol oxidation chemistry of CuII-Bc was explored using optical and 
kinetic methods. 
 
3.2 Materials and Methods 
Bacitracin and pyrocatechol (~99%) were purchased from Sigma–Aldrich Inc. 
(St. Louis, MO), the plasmid pQE30Xa was purchased from Qiagen (Valencia, CA), and 
3-Methyl-2-benzothiazolinone hydrazone hydrochloride monohydrate, 98%, was 
acquired from and Acros Organics (NJ).  Copper Sulfate (anhydrous) and 4-(2-
hydroxyethyl)-1-piperazineethanesulfonate buffer (HEPES) used for the oxidation study 
was purchased from Fisher Scientific Co. (Fair Lawn, NJ).  All chemicals were used 
without further purification.  All other solvents and reagents were the highest grade 
available from commercial sources.  Deionized (DI) water (18.2 MΩ) was obtained from 
a Millipore Milli-Q system.  Plastic ware and glassware were demetallized with EDTA 
and extensively rinsed.   All components were freshly prepared just prior to the 
experiments.  Quartz cuvettes were used in all the kinetic and optical studies. 
 
3.2.1 Kinetic Studies 
The catechol oxidation assay was carried out as previously described.32, 33  
Briefly, different concentrations of the substrate catechol ranging from 0.1 to 19.2 mM 
(along with each corresponding concentrations of MBTH as an ortho-quinone trapper) 
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were incubated with 20.0 μM (or 2.0 μM in H2O2 related experiments) CuII-bacitracin 
(1:1 metal-to-peptide stoichiometric ratio)  in 100.0 mM HEPES buffer at pH 7.0 and 25 
°C in the presence and absence of different H2O2 concentrations (0 to 64.0 mM).  All 
components were dissolved in DI water, and the final volume in the cuvette was fixed at 
1.0 mL.  The binding of oxidized o–quinone to MBTH formed a red adduct, which was 
monitored at 500 nm (ε = 32, 500 M–1cm–1)34 on a Varian Cary50 Bio UV-Vis 
spectrophotometer, and the initial rate was determined from the slope of the change in the 
absorbance with respect to time.   
The optimal ratio between the catalyst and substrate during catalysis was 
determined using the Job method with respect to catalytic activity. 35  The Job method is 
a continuous variation technique, where the concentrations of catalyst [CuII-Bc] and
substrate [CA] were varied while keeping the total concentration constant ([CuII-
Bc]+[CA] = 50.0 μM).  The result, with respect to activity, is plotted versus the mole 
fraction of catalyst (ΧCu(II)-Bc) or substrate (ΧCA).  The ratio of XCu(II)-Bc:XCA at which the 
activity reaches the maximum in the plot reflects the preferred stoichiometry of the (CuII-
Bc)-CA complex for the given experimental conditions.  Since the oxidation reaction 
follows the enzyme-like kinetics (discussed in the result section), the kinetic constants, 
such as KB and VMax, were determined by fitting the data to the Michaelis-Menten 
equation with the Sigma Plot 8.0.   
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3.2.2 Optical Studies 
The slow substrate 4,5-di-chloro-catechol (DCC) was used as a ligand in the 
binding study to show the interaction between the CuII-Bc complex and the catechol 
substrate.  Due to low solubility in water, DCC was dissolved in DMF.  The stock 
solution of the CuII-Bc complex was prepared in DI water, since only the peptide and not 
the copper salt would dissolve in DMF.  The experiment was run in DMF, and all 
components were completely miscible.  Briefly, DCC ranging from ~60.0 to 600.0 μM 
was gradually titrated into a 1.0 mL solution of CuII-Bc (300.0 μM) with the sample 
cuvette left in the spectrometer to keep the baseline intact.  The background was zeroed 
with only the solvent, and the mixture was scanned from 200 to 900 nm on the Varian 
Cary50 Bio UV-Vis spectrophotometer.  The dilution factor from each addition was 
corrected in the final concentrations.  The molar absorptivity value of the (CuII-Bc)-DCC 
complex was plotted with respect to the titrated DCC concentration, and the data fitted to 
simple 1:1 binding quadratic equation in Sigma Plot 8.0 for the determination of the 
affinity constant, KDCC. 
The stoichiometry of (CuII-Bc)-to-DCC binding was determined with the Job 
method.  As described in section 3.2.1, the metal complex [CuII-Bc] and ligand [DCC] 
were continuously varied while keeping a constant overall concentration ([CuII-
Bc]+[DCC] = 500.0 μM).  The maximum ratio (ΧCu(II)-Bc:ΧDCC) on the plot of the molar 
absorptivity of the (CuII-Bc)-DCC complex versus the mole fraction of DCC (ΧDCC) or 
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CuII-Bc (ΧCu(II)-Bc) indicates the preferred binding stoichiometry between the CuII-Bc 
complex and DCC. 
 
3.2.3  Anaerobic Studies 
For anaerobic experiments, the dissolved oxygen from all components was 
removed through freeze-thawing on a vacuum-argon line.  Briefly, the oxygenated 
solutions were first frozen in liquid nitrogen and then evacuated.  Next, the frozen sample 
was thawed in warm water, followed by application of pure Ar gas.  The process was 
repeated 5–8 times to ensure the removal of oxygen and replacement by Ar.  All 
components, except the catalyst, were transferred to the evacuated quartz cuvette with a 
gas-tight syringe.  The reaction was immediately monitored following the addition of the 
catalyst (CuII-Bc). 
 
3.2.4 DNA Cleavage Assay 
The 1:1 CuII-Bc stock solution was prepared by dissolving the peptide in 
ultrapurified water. The metal-complexes were freshly prepared in all experiments. The 
DNA cleavage assay contained 225 ng of plasmid DNA, 0.05% H2O2, and 25.0 μM of 
CuII-Bc in 100.0 mM HEPES at pH 7.00 and 37 °C in a volume of 25.0 μL. A time-
course (0–60 mins) experiment was performed and analyzed in a 1.0 % agarose gel 
stained with ethydium bromide, and then photographed on a transilluminator. 
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3.3 Results and Discussion 
A divalent metal ion is an essential cofactor for the biological activity of 
bacitracin.26  The metal-bound complex can bind the sugar carrier, C55-isoprenyl 
pyrophosphate, with high affinity.30  Furthermore, the CoII-Bc complex has been shown 
to interact with various phosphate derivatives through NMR studies.2b  Thus, in the 
presence of redox-active metal ion such as CuII, Bc can potentially interact and cause 
oxidative damage of biomolecules, such as DNA.   
The ability of (1:1) CuII-Bc to perform oxidative DNA cleavage was studied in 
the presence of H2O2 following the previously proposed protocol with a slight 
modification.32  The plasmid DNA (225 ng) was incubated with 25.0 μM CuII-Bc and 
0.05% H2O2 in 100.0 mM HEPES at pH 7.0 and 37 °C over a time course (0–60 mins).  
On the gel (Figure 3.2), the first lane is the 1 kb DNA molecular weight marker (M on 
gel), and the second lane is the reference (R on gel), which only contains the plasmid 
DNA (pQE30Xa) incubated over the same time course.  Lanes 1–5 represent different 
incubation times (i.e.  5, 10, 20, 40, 60 mins) for the CuII-Bc complex.  For the reference 
lane, both supercoiled (lower) and nicked circular (top) bands can be clearly seen.  In 
lanes 1–3 corresponding to 5, 10, and 20 mins incubation, a middle band of 
approximately 3.5 kbp based on the marker corresponds to a linearized plasmid from the 
manufacturer.  This indicates a double-stranded DNA cleavage has occurred.  In lanes 4 
and 5, corresponding to 40 and 60 mins incubation, the plasmid DNA is completely 
cleaved.  Short peptides with CuII binding ability have been shown to perform oxidative
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Figure 3.2.  Oxidative cleavage of 225 ng of plasmid DNA by 25.0 μM CuII-Bc with 
0.05% H2O2 in 100.0 mM HEPES buffer at pH 7.0 and 25 ºC.  The first lane is the 1 kb 
DNA molecular weight marker (M on gel), and the second lane is the reference (R on 
gel).  Lanes 1–5 represent different incubation times (i.e.  5, 10, 20, 40, 60 mins) for the 
CuII-Bc complex. 
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cleavage of plasmid DNA.  Thus, the above results suggest the ability of CuII-Bc to 
perform oxidation chemistry. 
The oxidation chemistry catalyzed by the CuII-Bc complex was further studied 
with catechol (CA) as a substrate.  Different concentrations of CA were incubated with 
20.0 μM CuII-Bc in 100.0 mM HEPES at pH 7.0 and 25°C.  The formation of the 
oxidized o-quinone product was followed optically, by monitoring the red adduct formed 
between the product and MBTH (an o-quinone specific indicator).  The catechol 
oxidation by the CuII-Bc complex increases with increasing amount of substrate and 
eventually reaches a plateau.  The observed saturation at higher concentrations of 
substrate suggests a possibility of enzyme-like pre-equilibrium kinetics shown below.  
The rate law for this reaction can be described accordingly to Eq. (1), with the 
assumption that [CA]>>[Cu(II)-Bc-CA]:   
 
[Cu(II)-Bc-CA][Cu(II)-Bc] + [CA] [Cu(II)-Bc] + o-quinone
k1
k-1
kcat
 
[ ]
[ ]CAK
CAV
B
Max
+=0ν  (1) 
where υ0 and VMax are the measured and maximum velocity, respectively, and 
1
1
k
kkK catB
−+=  is the virtual dissociation constant of the (CuII-Bc)-CA complex.  The 
data fits well to Eq. (1) to afford KB = 3.31 × 10–3 M, a first-order rate constant or the 
turnover number kcat (VMax/[Cu(II)-Bc]) = 6.99 × 10–3 s–1, and a second-order rate 
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constant or the catalytic efficiency kcat/KB = 2.11 M–1 s–1 (Figure 3.3).  Compared to the 
auto-oxidation rate constant of catechol (4.74 × 10–7 s–1) in the absence of CuII-Bc,32 there 
is a 1.47 × 104-time increase with respect to the first-order rate constant. 
The interaction between the CuII-Bc complex and the substrate catechol is 
confirmed by an optical binding study with a slow substrate, 4,5-dichlorocatechol (DCC).  
The activity of DCC is roughly 200 times slower than catechol with respect to kcat as a 
ligand.33  A 1.0-mL solution of 300-μM CuII-Bc was slowly titrated with DCC in DMF at 
25 °C.  The formation of complex was monitored from 200–800 nm on the Varian 
Cary50 Bio UV-Vis spectrophotometer.  Upon addition of DCC, a new absorption 
corresponding to a complex between CuII-Bc and DCC appears at approximately 304 nm 
(Figure 3.4).  The catecholate moiety has been previously proposed to bind the metal ion 
in a bidentate manner.36  A recent CoII binding study of bacitracin by means of NMR 
spectroscopy and molecular modeling suggested the presence of a possible hydrophobic 
binding pocket and the metal coordination sphere to be a distorted 5 or 6 instead of 4 
coordination.24  Thus, it may be possible for the catecholate moiety on DCC (or catechol) 
to bind the metalII center in a 1:1 stoichiometry to give a penta-coordinated sphere.  The 
plot of molar absorptivity (ε) value of the CuII-Bc-DCC complex at 304 nm versus the 
added equivalence of DCC can be fitted well to a 1:1 binding quadratic formula to afford 
the affinity constant, KDCC, of 2.40 × 104 M–1 (Figure 3.4 inset).  Even though the affinity 
constant can be determined from the fitting, the stoichiometry of the binding cannot be 
clearly abstracted.
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Figure 3.3.  Catechol oxidation by CuII-Bc in 100.0 mM HEPES at pH 7.0 and 25 ºC.  
The activity increases with increasing substrate concentration and reaches saturation at 
higher concentration, which may suggest an enzyme-like kinetics.  The data fits well to 
Eq. (1), affording KB, a first-order rate constant or the turnover number kcat (VMax/[Cu(II)-
Bc]), and a second-order rate constant or the catalytic efficiency kcat/KB of 3.31 × 10–3 M, 
6.99 × 10–3 s–1, and 2.11 M–1 s–1, respectively. 
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Figure 3.4.  4,5–dichlorocatechol (DCC) binding study of CuII-Bc in DMF.  DCC is 
added in 60.0 μM (0.2 equivalent) increment.  The CuII-Bc-DCC complex gives a strong 
absorption at 304 nm.  The changes in the absorbance at 304 nm with respect to the added 
DCC equivalence afford an affinity constant of 2.40 × 104 M–1 (the inset).  The spectra 
are baselined with the CuII-Bc complex prior to the addition of DCC. 
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Thus, the Job method was used to determine the stoichiometry of the (CuII-Bc)-
DCC complex.  The method calls for continuously varying the concentrations of the CuII-
Bc complex and DCC while keeping the overall concentration constant.35  For the optical 
study, the concentrations of the two components were arrayed to a total concentration of 
500.0 μM in 100.0 mM HEPES buffer at pH 7.0 and 25 ºC (i.e.  [CuII-Bc]:[DCC] = 500:0 
μM, 450:50 μM,…0:500 μM).  The absorption of the complex (310 nm) in buffer slightly 
shifted toward the higher wavelength (Figure 3.5).  As a result, the ratio that corresponds 
to the maximum intensity represents the preferred binding between CuII-Bc and DCC.  
The plot of the molar absorptivity value at 310 nm versus the mole fraction of DCC 
(ΧDCC) shows the maximum around 0.5 (0.5:0.5) which suggests that the stoichiometry of 
the preferred species is ΧCu(II)-Bc:ΧDCC = 1:1 (Figure 3.5 inset). 
Similarly, since an equilibrium is present between the CuII-Bc complex and 
substrate the interaction between the catalytic center (CuII-Bc) and substrate (CA) was 
further investigated with the Job method, monitored with the activity toward catechol 
oxidation.  The total concentration of [CuII-Bc]+[CA] was kept constant at 50 μM, and 
the experiment was conducted in 100 mM HEPES buffer at pH 7.0 and 25 ºC.  The result 
shows a gradual increase in activity with ΧCu(II)-Bc and reaches a maximum at ΧCu(II)-Bc = 
0.5, followed by a decrease in the activity of subsequent mole fractions which can be 
fitted to a 1:1 stoichiometry (Figure 3.6).  From the result, the most active species has a 
ratio of (CuII-Bc):CA = 1:1 (i.e.  0.5:0.5), establishing the equilibrium between reactants 
and the (CuII-Bc)-CA complex in the catalysis.
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Figure 3.5.  Optical Job plot of DCC binding tothe CuII-Bc complex.  The absorbance at 
310 nm versus the molar ratios between the CuII-Bc complex and DCC suggests that the 
stoichiometry of the preferred species is 1:1. 
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Figure 3.6.  Interaction between the CuII-Bc and catechol using the Job method.  The 
total concentration of the molar ratio is 50.0 μM.  The assays were performed in 100.0 
mM HEPES pH 7.0 buffer at 25 °C, and the interaction was monitored with the oxidation 
activity.  The plot of the initial rates versus the molar ratios indicates the preferred 
stoichiometry to be 1:1. 
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The results from the two binding studies (CuII-Bc:DCC = 1:1 and CuII-Bc:CA = 
1:1) using the Job method clearly indicate that the observed catechol oxidation chemistry 
occurs through a mononuclear CuII center.  The oxidation chemistry of mononuclear CuII 
systems has been thoroughly studied with synthetic ligand complexes, several 
spectroscopic techniques, and density functional theory (DFT) calculations.37  These 
studies have proven the important role of dioxygen in mononuclear CuII-center catalysis.  
Since the oxidation of catechol to o-quinone is a 2e– transfer process, the involvement of 
dioxygen in recycling of the metal center (CuI/CuII) is suspected.  Thus, the ability of 
CuII-Bc to perform catechol oxidation was determined in the absence of dioxygen (under 
anaerobic conditions). 
The dissolved oxygen in all components was removed by the method described in 
the experimental section.  The reaction (100.0 μM CuII-Bc and 2.5 mM CA) was 
performed in methanol, and the formation of o-quinone was monitored from 400–600 nm 
for 5 mins. (Figure 3.7).  The o-quinone-MBTH adduct immediately appears upon CuII-
Bc addition approximately at 500 nm.  A gradual and minor increase in the absorption 
from the first scan (Abs = 0.015) can be seen over 5-minute period and then stop 
increasing after 2–3 mins.  The difference in the intensity is estimated to be 0.010 (ΔAbs 
= 0.025 – 0.015), and the overall concentration of o-quinone is roughly estimated to be 
770 nM (based on εMBTH = 32, 500 M–1cm–1), which indicates a very inefficient catalysis.  
This is to be expected since a single CuII can only oxidize one of the two hydroxyl groups 
on catechol at a time.
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Figure 3.7.  The oxidation of 2.5mM catechol by 100.0 μM CuII-Bc under anaerobic 
condition.  The reaction was immediately monitored upon CuII-Bc addition up to 5 
minutes.  A small, gradual increase was observed up to 2–3 mins.  The change in 
absorbance is approximately 0.01. 
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The involvement of oxygen was further shown by introducing some air into the 
same sample and scanning over the same region.  An air-tight syringe was used to apply 
the air from the surrounding, and the listed air volume is based on the volume of the 
syringe.  As a result, this is a qualitative experiment.  From 5 to 40 mL of air was added 
into the mixture over 4 different occasions.  The increase in the absorbance was observed 
after each addition (Figure 3.8).  Quantification of the product based on the volume of air 
added is not feasible since factors such as the amount of oxygen in a given volume of 
syringe and the dissolvability of oxygen (which may be time-dependent) are not known.  
Qualitatively, however, this experiment clearly shows the importance of dioxygen in the 
observed mononuclear CuII-centered catechol oxidation. 
 The binding between copper and dioxygen depends on the oxidation state of metal 
(CuI vs. CuII) and the binding mode of dioxygen (end-on vs. side-on).   Two possible 
binding modes of dioxygen are end-on (η1) and side-on (η2) binding, where the dioxygen 
binds the metal ion in a monodentate and bidentate fashion, respectively.37  In the 
presence of a bidentate catechol, dioxygen may only be able bind the CuII-Bc center (a 3-
coordinated complex) through the end-on mode due to steric hindrance.  The steric effect 
is another important factor in the selection of dioxygen binding mode.  A classic example 
is the very first synthetic CuII-ligand complex, showing the mononuclear CuII-superoxo 
complex with a side-on binding mode, by Kitajima et. al. in 1994.38  The side-on binding 
by dioxygen in this complex was induced by steric effect of the ligand. 
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Figure 3.8.  Addition of air into anaerobic sample containing 100.0 μM CuII-Bc and 2.5 
mM CA.  The same air-tight syringe was used to suck up and bubble in the air from 
surrounding, and the listed air volume is based on the volume of the syringe.  From 5 to 
40 mL of air were added into the mixture over 4 different additions. 
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 Upon catechol binding, the CuII center may be reduced to CuI while the catechol 
is oxidized to a semiquinone.  Under aerobic conditions, the CuI can interact with 
dioxygen to give the following three potential copper-oxygen intermediates:  CuII-
superoxo (-O2–), CuII-hydroperoxo (-OOH) and CuIII-peroxo (-O22–).37  The CuIII-O22– 
species may not be the intermediate since side-on binding to the Cu center may not be 
possible (this binding mode will result in 7-coordination of the Cu).  On the other hand, 
both CuII-O2– and CuII-OOH species can have both end-on and side-on binding mode.  In 
its protonated form, the CuII-OOH species forms an end-on intermediate.  However, it 
can potentially form a side-on intermediate once deprotonated.37  The side-on binding 
mode may be too crowded in the metal coordination sphere as with the CuIII-O22–.  
Furthermore, a recently solved crystal structure of a mononuclear CuII enzyme, 
peptidylglycine α-hydroxylating monooxygenase (PHM), shows the end-on O2 binding of 
the Cu center.39  Thus, the end-on CuII-O2– or CuII-OOH species is very likely to be the 
intermediate. 
 Unlike oxygen, hydrogen peroxide (H2O2) prefers to bind the CuII center through 
a side-on mode upon full deprotonation, possibly forming the CuII-Bc-O22– intermediate.  
Hence, H2O2 was included in the reaction in order to determine its influence on the 
observed chemistry.  Different concentrations (0–64.0 mM) of H2O2 were incubated with 
20.0 μM CuII-Bc and 0.7 mM catechol in 100.0 mM HEPES buffer at pH 7.0 and 25 ºC.  
The increase in catechol oxidation was observed with increasing H2O2 and reaches 
saturation at higher concentrations of H2O2 (Figure 3.9 left panel).  As discussed above, 
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the saturation profile indicates the possibility of an enzyme-like kinetics, thus suggesting 
H2O2 as another substrate capable of binding to the metal center.  The data can be fitted 
to Eq. 2 to afford a kcat of 9.37 × 10–3 s–1 and an apparent binding or dissociation constant 
KH2O2 of 7.49 × 10–3 M for H2O2.  This value compared to KB = 3.31 × 10–3 M, the 
binding constant for catechol in the absence of H2O2, is approximately twice as higher, 
suggesting this substrate to bind ~2× lower than catechol toward the CuII-Bc complex. 
[ ]
[ ]22
22
0
22
OHK
OHV
OH
Max
Background ++=νν                    (2) 
Since both substrates (i.e.  both catechol and H2O2 show saturation) can 
independently bind to the Cu2+ center, it is essential to determine how the binding of one 
affects the other.  Different concentrations (0–9.6 mM) of catechol were incubated with 
the CuII-Bc (2.0 μM) complex in the presence of different H2O2 concentrations (0–64.0 
mM).  The enhancements in activity of catechol oxidation in the presence of H2O2 were 
clearly observed (Figure 3.9 right).  While KB is increased by ~7 folds, the addition of 
32.0 mM H2O2 in the assay increased the kcat and kcat/KB by 55 and 7 folds, respectively.  
Because the two substrates may bind to the CuII-Bc complex independently of each other, 
the Hanes plot can be used to determine the influence or relationship between the two 
substrates. 
From the Hanes analysis, the apparent binding equilibrium constants for both 
substrates and an intrinsic binding constant for one substrate can be calculated.40  The  
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Figure 3.9.  Hydrogen peroxide influence on the catechol oxidation by 2.0 μM CuII-Bc at 
pH 7.0 in 100.0 mM HEPES buffer at 25°C (right).  The concentrations of H2O2 were 
varied from 0 to 64.0 mM (right).  The titration of H2O2 at a constant catechol 
concentration of 0.7 mM displays saturation, which indicates the direct interaction 
between the CuII-Bc center and H2O2 (left).  20.0 μM CuII-Bc was used in the latter 
experiment (left). 
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Hanes analysis requires an initial linear treatment of the data in Figure 3.6 according to 
the following rate law (Eq. 3),  
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where  is the intrinsic binding constant for H2O2,  and  are the 
apparent binding constants for H2O2 and catechol, and 
Int
OHK 22
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OHK 22
0
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CatecholK
ν  and  are the experimental 
and maximum velocity, respectively (Figure 3.10 A).  The ratio between the 
corresponding apparent and intrinsic equilibrium constants for each substrate can suggest 
how the binding of one substrate affects the binding of another.  Then, the secondary 
plots of the fitted y-intercept (Eq. 4) and slope (Eq. 5) values versus 1/[H2O2] afford the 
two apparent equilibrium constants  = 1.91 × 10–2 M and  = 8.38 × 10–3 M 
and the intrinsic binding constant  = 9.03 × 10–3 M (Figure 3.10 B and C).   
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The ratio between the apparent and intrinsic binding constants is 2.53 for catechol 
(  /KB) and 2.11 for H2O2 ( / ), which suggests that both substrates are 
equally affected by the presence of the other.  Since O22– has been shown to bind Cu in a  
App
CatecholK
App
OHK 22
Int
OHK 22
 144
[Catechol] (M )
-0.002 0.000 0.002 0.004 0.006 0.008 0.010 0.012
[C
at
ec
ho
l]/
ν 50
0 (
s)
-4.0e+0
2.0e+5
4.0e+5
6.0e+5
8.0e+5
1.0e+6
0 m M  h2o2 
2 m M  h2o2 
4 m M  h2o2 
8 m M  h2o2 
16 m M  h2o2 
32 m M  h2o2  
64 m M  h2o2 
A
[H 2O 2]
-1 (M 1)
0 100 200 300 400 500 600
Sl
op
e C
at
ec
ho
l
0 .0
5.0e+6
1.0e+7
1.5e+7
2.0e+7
2.5e+7
B C
[H 2O 2]
-1 (M 1)
0 100 200 300 400 500 600
y-
in
te
rc
ep
t C
at
ec
ho
l
0 .0
2.0e+4
4.0e+4
6.0e+4
8.0e+4
1.0e+5
1.2e+5
 
Figure 3.10.  Hanes analysis of the oxidation of catechol by CuII-Bc at different 
concentrations of H2O2 (kinetic data from Figure 3.9 right).  Plot B and C are the replots 
of the slope and y-intercept values from plot A with respect to [H2O2]–1.  The apparent 
binding equilibrium constants for catechol ( ) and H2O2 ( ) as well as the 
intrinsic binding constant for H2O2 ( ) can be determined from the secondary plots. 
App
CatecholK
App
OHK 22
Int
OHK 22
 145
side-on (bidentate) mode,41 the reduction in the effectiveness of binding by catechol (also 
a bidentate binding) is expected due to inability of the CuII center to support a 7-
coordination sphere.  Thus, the observation described herein is more consistent with the 
end-on binding mode of HO2– when the catechol is bound to the metal center.   
 In the attempt to differentiate between a mononuclear and dinuclear CuII-centered 
catalysis, “redox-dilution” experiments were performed as previously proposed.33  Even 
though the studies above strongly suggest a mononuclear CuII-based catalysis, these 
interesting results, which may be of mechanistic relevance, are included.  Similar to the 
Job method, the concentrations of redox-inert ZnII to CuII were continuously arrayed with 
the total concentration kept constant ([ZnII]+[CuII] = 20.0 μM).  Two additional 
experiments with CoII and NiII in place of ZnII were performed.  The interaction between 
the two metal ions and the peptide was monitored with the catechol oxidation activity.  
The catechol (1.6 mM) oxidation by 20.0 μM metal-Bc complex was performed in 100.0 
mM HEPES buffer at pH 7.0 and 25 ºC.  Since Bc can bind both metals, the presence of 
ZnII-Bc complex can essentially “dilute” the redox activity of the CuII-Bc complex.   
A mononuclear versus dinuclear mechanism may be suggested based on the 
resulted pattern.  In a mononuclear mechanism, the ZnII complex has no influence on the 
redox activity of the CuII complex; thus, a linear trend is expected for the activity with 
respect to the CuII concentration.  However, the redox-inactive ZnII species can 
essentially interfere with the redox chemistry in the dinuclear mechanism by competing 
for the formation of the dinuclear center.  Thus, in the dinuclear mechanism, only a slow 
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and steady increase in the activity is expected up to 50% ZnII and 50% CuII ratio.  Then, a 
sharper increase in the activity is expected due to the presence of more CuII species for 
the formation of dinuclear center when the CuII to ZnII ratio surpasses 1:1, affording a 
sigmoidal-like pattern. 
The data can be fitted to the Hill equation (Eq. 6) which suggests the presence of 
cooperativity during the catalysis.  In the Hill equation,  
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υ and Vmax are the usual experimental and maximum velocity, respectively; KA is 
equivalent to the Michaelis constant accounting for all interactions; and θ is the fitted Hill 
coefficient that indicates the presence of cooperativity when greater than 1.33  The results 
for ZnII and CoII show an initial small and gradual increase in activity up to ΧCu(II) = 0.5, 
then followed by larger increase in activity (Figure 3.11 A and B).  A similar trend is 
observed for NiII; however, the sigmoidal-like nature is not as apparent (Figure 3.11 C).   
The sigmoidal-like patterns in the case of catechol oxidation by CuII-Bc in the 
presence of ZnII or CoII can be fitted to the Hill equation to afford θ = 1.93 (r2 = 0.99) and 
2.37 (r2 = 0.99), respectively (Figure 3.11 A and B), suggesting the presence of 
cooperativity.  For comparison, the results were also fitted with a simple 1:1 quadratic 
binding equation.  As shown in Figure 3.11, the 1:1 binding pattern for CuII binding to Bc 
may not be appropriate for fitting the data (the points deviate from the fitted dotted line), 
showing the r2 values of 0.92 and 0.89, respectively, for ZnII and CoII dilution.  The 
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difference in r2 values for the Hill (r2 = 0.991) and quadratic (r2 = 0.986) equation, unlike 
for ZnII and CoII, is less apparent for NiII.  This is also reflected in the Hill coefficient of 
1.38. 
At a first glance, the presence of cooperativity can suggest a di-CuII center 
catalysis.  Nevertheless, the optical (DCC binding) and mechanistic (catechol oxidation) 
Job data strongly indicate a mononuclear CuII center oxidation chemistry.  The results 
from the latter two experiments also suggest the binding of catechol to the CuII center in a 
bidentate manner (i.e. ΧCu(II) = 0.5).  A possible explanation for the presence of 
cooperativity is the electron transfer between the nearby CuII-Bc complexes.  Thus, when 
the metalII:CuII ratio is greater than 1:1 (ΧCu(II)>0.5), the increase in CuII-Bc (higher 
probability to be in close proximity) species corresponds to increase in activity.  
Structural change upon metal binding was observed, which might account for the 
cooperativity.24  Although not common, the presence of cooperativity between two CuII 
centers in close proximity has been described in PHM and DβM for a mononuclear CuII 
center oxidation chemistry.42  PHM is responsible for C-H bond hydroxylation of C-
terminal glycine, and DβM hydroxylates the benzylic C-H bond of dopamine to generate 
norepinephrine.  Even though they are di-Cu enzymes, their Cu centers (CuM and CuH) 
are ~11 Å apart,37 and only CuM, the active site, directly interacts with the substrate and 
oxygen.42  As a result, these proteins are still categorized as mononuclear Cu 
monooxygenases.  However, CuH has been proposed to perform a long-range transfer of 
an electron to the CuM site for regeneration of CuI from CuII.43 
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Figure 3.11.  ZnII (A), CoII (B), and NiII (C) dilution of CuII for the analysis of 
mononuclear versus dinuclear metal center in the catalysis of catechol oxidation by CuII-
Bc.  The experiments were followed by the oxidation of catechol in pH 7.0 100.0 mM 
HEPES buffer at 25 °C.  The two metal ions were arrayed in different ratios while the 
overall concentration of all the metal ions was fixed.  The data can be better fitted to the 
Hill equation (solid trace) than the quadratic equation for a simple 1:1 binding (dashed 
trace). 
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Based on the experimental results, the following mechanism is proposed for the 
oxidation of catechol by CuII-Bc through a mononuclear Cu center (Figure 3.12).  First, 
catechol binds to the CuII center in a bidentate manner, followed by 1e– transfer to CuII to 
afford a CuI-semiquinone complex (step A and B).  The CuI-semiquinone complex binds 
O2 and transfers 1e– to O2 give a CuII-superoxo-semiquinone complex (step C).  The 
semiquinone is further oxidized to give o-quinone and a CuII-peroxo complex (step D).  
The CuII-peroxo complex can go through another cycle since O22– can take 2 more e– 
before released as 2H2O, or H2O2 can be released with a regenerated CuII center (step E). 
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Figure 3.12.  Proposed mechanism for catechol oxidation by CuII-Bc through a 
mononuclear CuII center catalysis in the presence of O2.  First, catechol binds to the CuII 
center in a bidentate manner, followed by 1e– transfer to CuII to afford a CuI-semiquinone 
complex (step A and B).  The CuI-semiquinone complex binds O2 and transfers 1e– to O2 
give a CuII-superoxo-semiquinone complex (step C).  Then, the semiquinone is further 
oxidized to give o-quinone and a CuII-peroxo complex (step D).  The CuII-peroxo 
complex can go through another cycle since O22– can take 2 more e– before released as 
2H2O, or H2O2 can be released with a regenerated CuII center (step E).  In the absence of 
O2, the oxidation is not catalytic.
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3.4 Conclusions 
Bacitracin, a dodecapeptide with a cyclic structure, is a naturally occurring potent 
antibiotic specifically against Gram positive bacteria.2  It is an effective component of 
probably the most used topical antibiotic ointment in North America.  While topical 
application of this antibiotic is considered safe, a systemic administration has been 
proposed to cause nephrotoxicity.2  The proposed antibacterial mechanism involves the 
inhibition of bacterial cell wall synthesis by the tight binding of ZnII-Bc complex to the 
pyrophosphate group of lipid sugar carrier.26, 29, 30   
In this study, I have shown the ability of bacitracin to perform oxidation 
chemistry in the presence of redox-active CuII.  A high affinity binding of metallo-Bc to 
C55-isoprenyl pyrophosphate29 as well as the NMR study of binding between CoII-Bc and 
several phosphate derivatives2b led to the hypothesis that the CuII-Bc complex may bind 
DNA through the phosphate moiety and perform the oxidative cleavage of DNA.  Indeed, 
oxidative cleavage of plasmid DNA by CuII-Bc was observed (Figure 3.2).  The oxidation 
chemistry of CuII-Bc was studied with catechol as a substrate.  The substrate was indeed 
observed to be oxidized effectively by CuII-Bc in the absence and presence of 32.0 mM 
H2O2, showing first-order rate constant of 6.99 × 10–3 s–1 and 9.37 × 10–3 s–1, 
respectively, accounting for a rate enhancement of 1.47 × 104 and 1.98 × 104 fold, 
respectively with respect to the auto-oxidation under the same condition. 
Studies using the Job method, an optical binding of a slow substrate, 4,5-
dichlorocatechol, (1:1 CuII-Bc-DCC) and a mechanistic binding of catechol (1:1 CuII-Bc-
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CA) with the CuII-Bc complex nicely suggest a mononuclear CuII center oxidation 
chemistry.  Since catechol oxidation is a 2e– transfer process, oxygen must be involved in 
the redox cycling of the Cu (CuII/CuI) center.  The 1:1 binding indicates a bidentate 
binding of CA to the CuII center, which results in a 5-coordination sphere.  This further 
leads to the proposal of a monodentate end-on oxygen binding.  Furthermore, “dilution” 
experiments indicate the possible presence of cooperativity.  A mechanism is postulated 
based on the experimental results (Figure 3.12). 
Upon catechol binding (in a bidentate manner) to the CuII center, an electron is 
readily transferred to the Cu center to form a CuI-bound semiquinone (Figure 3.12 steps 
A and B).  Next, dioxygen binds to the CuI center in an end-on (η1) mode.  This is 
immediately followed by transfer of an electron from the Cu center to the oxygen, 
affording a CuII-superoxo intermediate (Figure 3.12 step C).  The semiquinone is then 
fully oxidized to o-quinone and released after another electron transfer to the Cu center 
(Figure 3.12 step D).  The bound oxygen may be able to accept up to four electrons 
before released as two water molecules, or H2O2 and a regenerated CuII center may be 
released without further electron transfer (Figure 3.12 step E).44  A possible presence of 
cooperativity between nearby CuII-Bc complexes may also be suggested.  Furthermore, 
the cooperativity may be explained by the bridging of dioxygen to two different CuII-Bc 
complexes, which may help stabilize the overall structure. 
The chemistry of di-CuII centers with oxygen has been extensively studied and 
well characterized with a combination of synthetic organic models, multiple 
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spectroscopic techniques, and DFT calculations.45  Although our understanding of 
mononuclear CuI/II centers has increased recently, it is still a work in progress.  The above 
proposed mechanism is deduced based on limited information from the experimental 
results and our understanding of mononuclear Cu systems.  Thus, further detailed kinetic 
experiments combined with spectroscopic techniques, such as EPR and resonance Raman 
spectroscopy, are essential to validate the oxidation mechanism of CuII-Bc. 
 In general, bacitracin is a relatively safe antibiotic.  Because of its low intestinal 
absorption, bacitracin has been globally utilized as animal feeds to prevent bacterial 
infections in farm animals.4  In addition, it has been largely used as wound prophylaxis in 
hospitals and on tattoo wounds.10  However, there is an increase in reported cases of 
allergic reactions from this drug recently.  An earlier study has proposed these allergic 
reactions to be due to polymerization of bacitracin into macromolecules with high 
molecular weight.46  Metal-induced conformational changes and aggregations are 
commonly observed among small peptides and proteins especially by redox-active CuII 
and FeIII.47  Thus, the oxidation chemistry of CuII-Bc reported in this chapter may 
potentially contribute toward the allergic reactions caused by bacitracin. 
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CHAPTER 4 
 
 
ELUCIDATION OF THE IN VITRO OXIDATION CHEMISTRY OF 
COPPER(II)–HISTATIN 5 COMPLEX BY MEANS OF REACTIVITY STUDIES 
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4.1 Traditional Antibiotics 
The serendipitous discovery of penicillin (isolated from Penicillium notatum) by 
the bacteriologist and immunologist Sir Alexander Fleming of Ayrshire, Scotland in 1928 
marked the beginning of the use of naturally occurring antibiotics.1,2  It is inarguably one 
of the most important discoveries in the field of medicine in the 20th century.  Although 
Fleming published his findings in 1929, the clinical application of penicillin was not fully 
established until 1940 by chemist Ernst Boris Chain (Berlin, Germany) and pathologist 
Howard Walter Florey (Adelaide, South Australia).  The three shared the Nobel Prize for 
their findings in 1945.1,2  Since then, antibiotics have been irreplaceable weapons against 
disease-causing microbes.   
By definition, antibiotics are chemical substances produced by bacteria and fungi 
to selectively inhibit the growth or survival of other organisms.  In general, they deter the 
growth of microorganisms by interacting with DNA/RNA (e.g.  FeII-bleomycin can bind 
and cleave DNA and RNA molecules through O2 activation.3) and the cell membrane 
(e.g.  gramicidin can penetrate and span the lipid bilayer, leading to eventual bacterial 
cell death.4), preventing cell wall synthesis (e.g.  penicillin prevents bacterial cell wall 
synthesis by binding irreversibly to the DD-transpeptidase or the penicillin binding 
protein, which is responsible for cross-linking polysaccharide chains.5), or inhibiting 
protein synthesis (e.g.  tetracycline inhibits protein synthesis by binding to the 
ribosome.6).  They are effective against a broad spectrum of infectious microbes, ranging 
from Gram positive and negative bacteria to fungi.  In addition, some have antitumor and 
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anticancer properties.3  Thus, naturally-occurring antibiotics such as aminoglycosides, 
cephalosporins, macrolides, and vancomycin were considered “wonder drugs” and were 
extensively used.  As a result of such extensive as well as improper usages (such as 
incorrect dosing and treatment duration) over the years, bacterial resistance has become 
an alarming issue.  For example, streptococci became resistant to penicillin only after one 
year of use,7 while tetracycline is obsolete against many bacteria6,8 and vancomycin is 
gradually losing its potency.9  Furthermore, there are different levels of toxicity 
associated with many antibiotics, ranging from minor (i.e.  headache, diarrhea, and 
nausea) to serious (i.e.  cardiotoxicity, ototoxicity, and nephrotoxicity) side effects, 
reducing effectiveness in their applications. 
 
4.1.1 Antimicrobial Peptides (AMPs) 
In the early 1970s, a new way of combating infectious microorganisms came with 
the discovery of peptides having antimicrobial activities.  They are commonly called 
antimicrobial peptides (AMPs) and are found in both plants and animals.10  In human, 
AMPs are an essential part of the innate immunity, where they form the first line of 
defense against the invading pathogens in various locations of the body.  These natural 
antibiotics are typically small cationic peptides of 3–6 kDa. 11  Although their amino acid 
compositions vary, these peptides have been suggested to have similar structural motifs, a 
random coil in an aqueous environment and an α-helical or a β-sheet conformation in a 
hydrophobic environment.12   
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AMPs display a wide range of antimicrobial activities against Gram-positive and -
negative bacteria, fungi, parasites, protozoa, and some viruses.  A generally accepted 
antibacterial mechanism of these peptides is their ability to penetrate the bacterial 
membrane and create pores through charge–charge (positively charged peptide and 
negatively charged cell membrane) interactions, which lead to cell death as a result of 
cytoplasmic leakage.10  Nevertheless, AMPs have also been suggested to interact with 
DNA, RNA, and specific proteins or enzymes as well as inhibit DNA, protein, or cell 
wall synthesis.  Buforin II, a 21-amino acid antimicrobial peptide, is isolated from the 
stomach tissue of the Asian toad, Bufo bufo garagriozans, and causes cell death by 
binding to DNA and RNA.13   
In addition to their antimicrobial functions, these antibiotic peptides are also 
associated with the processes in immunomodulation and detoxification.  They can act as a 
flag in directing immune or inflammatory cells to the infectious sites, can enhance 
angiogenesis and wound healing, and can bind and neutralize lipopolysaccharides (LPSs).  
LPSs are released from the lysed bacterial cell wall as a result of antibiotic treatment.  
These molecules can over-activate the host’s immune system, which can ultimately lead 
to lethal endotoxicity.14  In addition, a salivary peptide, histatin 5, prevents the toxic 
tannin from intestinal absorption by binding and precipitating out the plant toxin.15  
Moreover, some of these peptide antibiotics have antiviral or anticancer properties other 
than their normal antimicrobial activities (antibacterial and antifungal).  The three well-
studied AMPs in humans are defensins, cathelicidins, and histatins.10c  Other well known 
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AMPs are the amphibian peptides, magainins and dermaseptins, and the insect peptides, 
cecropins and melittins.10b  
 
4.1.2 Candida albicans 
Human oral mucosa, a highly permeable tissue that lines the oral cavity, houses 
over 200 bacterial and fungal species.16  The oral cavity in which these microbes reside is 
consisted of the saliva, the tongue, and the tooth-associated supra-gingival and sub-
gingival plaques.  While the Streptococcus species make up the majority of the bacterial 
flora, the Candida species are the most predominant among the fungal families, including 
Candida albicans, C. dubliniensis, C. glabrata, C. krusei, and C. tropicalis.16  Up to 80% 
of healthy individuals have been suggested to retain these fungal microbes at various 
regions of the body (i.e.  the oral cavity, lungs, the gastrointestinal tract, the vaginal tract, 
blood, and skin) but mostly in the oral cavity.  Furthermore, these fungi are prominent 
(65–80%) among healthy children, the elderly, and HIV patients.16   
Under normal circumstances, these fungal microorganisms are kept under control 
by the host’s innate defense, the whole saliva.  Nevertheless, this delicate equilibrium is 
disrupted in immunosuppressed or immunocompromised individuals, and conditions such 
as diabetes mellitus, immunosuppressive therapy, Sjogren’s syndrome, radiation therapy 
for head and neck tumour, and HIV infection can lead to candidiasis.16  Moreover, C. 
albicans makes up the largest percentile among the above-listed fungi and mainly 
implicated in HIV-related oral candidiasis (up to 90%).16  Thus, the severity of its 
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infections can be used as an indicator for the disease progression in AIDS, owing to the 
prominent nature of oral candidiasis among immunocompromised patients.17  Although 
oral fungal infections are transient for the healthy individuals, they can be progressively 
infectious and may even be lethal for the immunodeficient HIV-infected adult and 
pediatric patients.  In fact, the rise in the antifungal drug resistance has increased the 
mortality rate among AIDS patients over the years.18 
Whole saliva contains arrays of antimicrobial peptides and proteins that help 
control infections caused by these fungal microbes; some of the well-studied ones are 
mucins, histatins, defensins, calprotectin, myeloperoxidase, lysozyme, lactoferrin, 
secretory leukoprotease inhibitor, and proteolytic peptide fragments.16  In the case of 
fungal infections among the immunosuppressed individuals such as HIV patients, a 
number of drugs have been used:  5-fluorocytosine, the polyenes (i.e.  amphotericin B 
and nystatin), and the azole-based antifungal drugs (i.e.  triazole fluconazole).  However, 
the fungal drug resistance has become an alarming issue over the years similar to the 
antibiotic resistance in bacteria.19  As a result, scientists are intensely studying the 
naturally-occurring antimicrobial peptides in hopes of finding a new way to combat those 
opportunistic microorganisms. 
 
4.1.3 Histatin 5 (Hn5) 
The search for a salivary component that enhances the glycolysis of oral 
microorganisms led to the discovery of a small basic peptide,20 which was later 
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determined to have multiple congeners and termed histatins (Hn) owing to their histidine-
rich primary structures.21, 22  The ability of these peptides to bind hydroxyapatite with 
high affinity23 and the difficulty in the separation of the congeners initially interested 
researchers.24  Histatins are a family of histidine-rich cationic peptides secreted from the 
parotid and submandibular glands.22  Along with other salivary proteins and peptides, 
such as proline-rich proteins and defensins, histatins possess antimicrobial (against 
Streptococcus mutans)25 and antifungal (against Candida albicans) properties and are 
active especially toward one of the most prevalent and opportunistic pathogenic yeasts, 
Candida albicans.26  In addition, Hn5 show antifungal activity against Cryptococcus 
neoformans and Saccharomyces cerevisiae27 as well as azole-resistant strains of 
Candida.28 
 
 
4.1.3.1 Structure of Histatins 
Histatins are present only in higher primates.  Two genes, HTN1 and HTN2 
localized on chromosome 4q13, are responsible for the synthesis of histatin 1 
(DpSHEKRHHGY10 RRKFHEKHHS20 HREFPFYGDY30 GSNYLYDN) and histatin 3 
(DSHAKRHHGY10 KRKFHEKHHS20 HRGYRSNYLY30 DN), respectively.29, 30  
Histatin 1 is composed of 38 amino acids, with Ser-2 phosphorylated; whereas, histatin 3 
is made up of 32 amino acids, having similar sequence as histatin 1.22  Shorter variants of 
these two peptides have been isolated and identified, which have also been shown to be 
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active toward C. albicans.  Histatin 5 (Hn5), consists of the first 24 amino acids of 
histatin 3, is the most active fragment at physiological concentrations (15–30 μM).  Hn5 
is expressed at the highest concentration among the variants in human saliva.  Hn1, 3, and 
5 make up 85–90% of all histatin peptides in the whole saliva,22 and the variants are the 
proteolytic products with different antifungal activities toward C. albicans.31   
Based on a circular dichroism study, the full length along with several shorter 
length peptides (the shortest fragment is made up of 10 C-terminal amino acid residues) 
of Hn5 have different tendencies to form α-helices in hydrophobic environments; 
whereas, the random coil conformation is favored in aqueous environments.  The same 
study suggests that the C-terminal (a minimum of 14 amino acids) but not the N-terminal 
residues of Hn5 are essential for appreciable candidacidal activity.  The α-helical 
conformation is not required for its function, since less active fragments can also assume 
such secondary structure.32   
 
4.1.3.2 Antimicrobial Mechanisms of Histatin 5 
Even though the antibacterial and antifungal activities of histatins have been 
confirmed,25, 26 the antibiotic mechanism is still unclear.  Two mechanisms have been 
proposed in the explanation of antimicrobial activity of Hn5.  Initially, Hn5 was proposed 
to damage cell membranes, which result the release of K+ ions that are associated with 
the loss of cell viability.25, 26  However, unlike other antimicrobial peptides, Hn5 has a 
weak amphipathic nature and lack the ability to form pores in the bacterial cell 
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membranes.33  The calcein dye permeability study by Edgerton et. al. supports this 
hypothesis by proposing that the release of intracellular calcein from C. albicans is the 
aftermath of cell death and is not associated with cytotoxicity.34  In this study, it was 
proposed that the peptide destabilizes the cell membrane, followed by the interaction with 
specific cellular components leading to cell death and cytoplasmic leakage (which takes 
place after cell death).34  The same group later proposed that Hn5 induces cell death 
through non-lytic release of ATP.35  In this mechanism, Hn5 intially interacts and binds 
to Ssa1/2, the heat shock protein on the cell wall of C. albicans and internalized.36  After 
entering the cell wall, Hn5 interacts with TRK1, the potassium transporter, leading to the 
loss of cell integrity.37  Extracellular ATP, in turn, binds and activates purinergic-like 
receptors, leading to apoptosis.35   
Oppenheim and co-workers proposed a different mechanism that involves the 
disruption of the yeast’s respiratory machinery.38  According to this group, the Hn5 
peptide is first internalized, possibly by translocation down the membrane-potential 
gradient.  This is followed by further internalization of the peptide into the mitochondrion 
through a similar mechanism.  The internalization of Hn5 has been shown by the 
aggregated intensity of the fluorescent agents, tetramethylrhodamine isothiocyanate and 
fluorescein isothiocyanate, coupled to Hn5 in mitochondria.38b  Once inside, Hn5 
interferes with the electron transfer processes, which leads to the generation of reactive 
oxygen species (ROS).  The presence of ROS was confirmed by the accumulation of the 
oxygen radical sensitive fluorescent probe, dihydroethidium, in mitochondria.38a  
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Furthermore, they suggested that cellular respiration is necessary for the candidacidal 
activity since respiratory inhibitors such as cyanide and azide as well as anaerobic 
conditions reduce or prevent the antifungal activity of Hn5.  The disruption of cellular 
respiration and the oxidative damages to biological molecules caused by ROS lead to 
eventual cell death.38 
 
4.1.3.3 Metal-Binding of Histatin 5 
Having multiple histidine residues allows Hn5 to have great flexibility in binding 
metal ions.  Hn5 has a high-affinity CuII and NiII binding site (Asp-1-Ser-His known as 
ATCUN—Amino Terminal CuII- and NiII-binding)39 on the N-terminus and a preferential 
ZnII binding site (HEXXH motif)40 on the C-terminus.41  The affinity constants 
determined from an isothermal calorimetry study are 2.6 × 107 M–1 and 1.2 × 105 M–1 for 
the CuII- and ZnII-binding site, respectively.42  In addition to CuII and ZnII, Hn5 can bind 
NiII, CaII, and FeII, although the binding affinities for the latter two are very weak.  The 
order of metal binding to Hn5 is CuII > NiII > ZnII in aqueous environments.  Both Hn3 
and Hn5 have been shown to be able to bind more than one (and up to 5) equivalent of 
metal ions.41   
A different study shows the binding of Hn5 to divalent transition metals, such as 
CuII, NiII, and ZnII, and displays DNA nuclease activity.43  It was shown that the  CuII 
complexes of synthetic variants of Hn5, containing both the ATCUN and HEXXH 
regions, can damage plasmid DNA through redox chemistry.  Based on NMR results, it 
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was suggested that the peptide structure is stabilized by metal binding.  In a recent study 
by the same group, another short ATCUN containing synthetic variant of Hn5 was 
proposed to have a pro-oxidant activity.44  They proposed a possible generation of ROS 
by Hn5 in the presence of CuII, supporting the ROS-induced antimicrobial mechanism.  
ROS generation was proposed to follow oxygen activation by the CuII-Hn5 complex. 
It is apparent that there is a trend in the ability of CuII-binding peptides to perform 
oxidation chemistry.  This has been demonstrated in recent studies, where the short 
soluble and metal-binding fragments of amyloid peptides have been shown to perform 
catechol- and phenol-oxidase-like chemistry in the presence of CuII.45, 46  The oxidation 
mechanism has been proposed to involve oxygen binding and activation through a 
transient di-CuII center.  Another example is the antibiotic peptide, bacitracin, discussed 
in the previous chapter.  Bacitracin, however, appears to perform a mononuclear Cu-
centered catalysis, based on experimental results.  In both cases, only one CuII ion can 
bind to the peptide.  With histatin 5, at least two CuII ions can bind to each peptide, owing 
to the presence of 7 histidine residues.  Thus, it will be interesting to study the potential 
oxidation chemistry with a peptide containing more than one binding site in the sequence 
which is the theme of this chapter. 
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4.2 Materials and Methods 
Histatin 5 (Hn5) was synthesized and the purity determined using MALDI-TOF 
mass spectrometer at the University of South Florida Peptide Synthesis and Mass 
Spectometry Center.  Copper Sulfate (anhydrous) and 4-(2-hydroxyethyl)-1-
piperazineethanesulfonate buffer (HEPES) used for the reactivity experiments was 
purchased from Fisher Scientific Co. (Fair Lawn, NJ).  Pyrocatechol (~99%) and 3-
Methyl-2-benzothiazolinone hydrazone hydrochloride monohydrate (98%), MBTH, were 
acquired from Sigma–Aldrich Inc. (St. Louis, MO) and Acros Organics (NJ), 
respectively.  All chemicals were used without further purification.  All other solvents 
and reagents were of the highest grade available from commercial sources.  Deionized 
water (18.2 MΩ) was obtained from a Millipore Milli-Q system.  Plastic ware and 
glassware were demetallized with EDTA and extensively rinsed.   All components were 
freshly prepared prior to the experiments. 
 
4.2.1 Kinetic Studies 
  Catechol oxidation assays were carried out as previously described.46  Different 
concentrations (0–6.4 mM) of catechol (with equal concentrations of o-quinone specific 
indicator, MBTH) were incubated with 5.0 μM CuII–Hn5 (4:1 metal-to-peptide) in the 
presence and absence of H2O2 in 100.0 mM HEPES buffer at pH 7.0 and 25 ºC.  The final 
volume in the cuvette is 1.0 mL.  The oxidized o–quinone can bind to MBTH to form a 
red adduct, which was monitored at 500 nm (ε = 32, 500 M–1cm–1)47 on a Varian Cary50 
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Bio UV-Vis spectrophotometer equipped with a water peltier PCB-150 thermostable cell 
(Varian, Palo Alto, CA).  The initial rate was determined from the slope of the change in 
the absorbance with respect to time (0–5 mins) in the linear region.  The kinetic 
constants, KM and kcat, were determined by fitting the data to the Michaelis-Menten 
equation in the Sigma Plot 8.0. 
 
4.2.2 Optical Studies 
The slow substrate, 4,5-di-chloro-catechol (DCC), was used as a ligand in binding 
studies to show the interaction between the CuII-Hn5 complex and the catechol substrate.  
Due to low solubility in water, DCC was dissolved in DMF.  The stock solution of the 
CuII-Hn5 complex was prepared in DI water, since only the peptide and not the copper 
salt would dissolve in DMF.  The experiment was performed in DMF, and all 
components were completely miscible.  Briefly, DCC ranging from 0 to 1.0 mM was 
gradually titrated into a 1.0mL solution of CuII-Hn5 (200.0 μM) with the sample cuvette 
left in the spectrometer to keep the baseline intact.  The background was zeroed with only 
the solvent, and the mixture was scanned from 200 to 900 nm on the Varian Cary50 Bio 
UV-Vis spectrophotometer.  The dilution factor from each addition was corrected in the 
final concentrations.  The molar absorptivity value of the CuII-Hn5-DCC complex was 
plotted with respect to the titrated DCC concentration, and the data was fitted to simple 
1:1 binding quadratic equation in Sigma Plot 8.0 for the determination of the affinity 
constant, KDCC. 
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 4.2.3 NMR Studies 
1H NMR spectra were acquired on Varian INOVA500 spectrometer (at 500 MHz 
1H resonance) with a 5-mm bio-TR (triple resonance) probe.  A 90° pulse (~9μs) was 
used for the acquisition of 1D 1H NMR spectra with 8 K data points.  The superWEFT 
technique48 was used for the suppression of slowly relaxing signals.  Both peptide and 
cobalt stock solutions were prepared in d6-DMSO.  Hn5 peptide sample (0.5 mM) was 
titrated with CoII, and the complex formation was monitored over 300 ppm spectral width 
(–150 to 150 ppm).  Triethylamine was added as needed.  A line-broadening of 40 Hz 
was applied to improve the signal-to-noise ratio of the paramagnetically shifted signals. 
 
4.3 Results and Discussion 
There are 7 histidine residues on Hn5, which afford more than one metal-binding 
site.  Metal-binding studies have been previously done for Hn5, and two possible sites 
were proposed:  a high-affinity CuII and NiII binding site on the N-terminus (known as 
ATCUN—Amino Terminal CuII- and NiII-binding)39 and a preferential ZnII binding site 
on the C-terminus (HEXXH motif)40.  However, up to 4 equivalents of CuII have been 
suggested to bind 1 equivalent of Hn5 peptide.41  Thus, a 4:1 CuII-to-Hn5 complex was 
used in the reactivity studies.   
 Only two metal binding motifs have been proposed for Hn5 although this peptide 
of 24 amino acids has 11 possible metal binding residues (i.e.  1 Asp, 1 Glu and 2 Tyr in 
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addition to 7 His residues).  A recent study on ZnII and CuII binding by means of 
isothermal calorimetry suggests that Hn5 has three possible metal binding sites for both 
metals.42  Since the presence of 2 versus 3 CuII ions may react with catechol differently, it 
is essential to know how many CuII ions are bound per Hn5 peptide.  Thus, CuII binding 
by Hn5 was studied by means of optical, EPR, and NMR spectroscopy to determine the 
stoichiometry. 
 The optical CuII titration was performed in 100.0 mM HEPES buffer at pH 7.0 
and 25 ºC on Cary50 spectrophotomer.  Hn5 (200.0 μM) was gradually titrated with CuII 
and the electronic spectrum collected from 200–800 nm.  Upon CuII addition, two strong 
absorptions around 250 and 300 nm and a d–d transition absorption at ~520 nm were 
observed (Figure 4.1).  As more CuII is added, a gradual red shift by all three signals was 
observed.  The sample was titrated with up to ~6.0 equivalents of metal, resulting in ~100 
nm shift in the d–d transition.  The resulted electronic spectra suggest the presence of 
more than one CuII-bound Hn5 species.  Since the number of species present cannot be 
clearly distinguished from the electronic spectra, the CuII binding was further investigated 
with EPR spectroscopy. 
 The continuous-wave (CW) EPR spectra of CuII-Hn5 complexes were acquired on 
a Bruker Elexsys E580 cw X-band spectrometer assisted by Dr. Angerhofer at the 
University of Florida.  The spectra were acquired on the following complexes of CuII  
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Figure 4.1.  Optical CuII binding study of Hn5 (200.0 μM) in 100.0 mM HEPES buffer at 
pH 7.0 and 25 ºC.  Approximately 100.0 μM CuII (0.5 equivalent) is added for each 
spectrum.  The inset is the expansion of the wavelength from 400–800 nm.  A gradual 
shift in all three observed signals was observed upon addition of metal.  The d–d 
transition at ~520 nm shifted approximately 100 nm after up to ~6.0 equivalents of CuII 
has been added.
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-(250.0 μM) Hn5 in DMF:  1:1, 2:1, and 4:1 (Figure 4.2 and 4.3).  The spectra display 
characteristics typical of CuII complexes, having 4 hyperfine splittings in an axial 
orientation (i.e.  gx = gy < gz), with “overshoot” signals.  The magnetic field is converted 
into g values, and the spectra are plotted with respect to g values (on x-axis).  The g-
parallel values for 1:1 and 2:1 species are approximately 2.198 and 2.269, respectively, 
while the g-perpendicular value is estimated to be 2.062 for both species (Figure 4.2).  In 
the spectrum for 1:1 CuII-Hn5, only one set of hyperfine splittings can be clearly seen; 
whereas, in the 2:1 spectrum, another set of hyperfine signals in addition to the former is 
apparent.  The difference in the g values also indicates the presence of two different CuII 
species in 2:1 spectrum, and these values fall within the normal range for CuII species 
bound to nitrogen-donor ligand such as histidine.49  At 4:1 species, the hyperfine 
splittings of 1:1 and 2:1 species are replaced by a single set of hyperfine signals with g-
parallel and g-perpendicular values of 2.313 and 2.082, respectively (Figure 4.3).  Based 
on the clear difference between 1:1 and 2:1 versus 4:1 species indicates there may be two 
or more types of CuII centers present at 4 equivalents of CuII. 
Next, the metal coordination by Hn5 was further defined by means of NMR 
spectroscopy.  The slow electronic relaxation of CuII can broaden the NMR signals 
beyond detection, rendering it useless in metal-binding studies by means of NMR 
spectroscopy.  However, fast relaxing CoII has been effectively utilized as a paramagnetic 
NMR probe in studying the metal-coordination site of various systems.50  A 0.5-mM apo-
Hn5 peptide sample was gradually titrated with CoII in d6-DMSO, and the  
 182
g-values
2.02.22.42.6
A
rb
itr
ar
y 
E
PR
 In
te
ns
ity
-20000
-15000
-10000
-5000
0
5000
10000
15000
1:1 CuII-to-Hn5
2:1 CuII-to-Hn5
 
g║ = 2.269
⊥g  = 2.062
g║ = 2.198
Figure 4.2.  EPR spectra of 2:1 (dotted line) and 1:1 (solid line) CuII-(250.0 μM) Hn5 in 
DMF.  The g-parallel values for 1:1 and 2:1 species are 2.198 and 2.269, respectively, 
while the g-perpendicular value is estimated to be 2.062 for both species.  The 2:1 
spectrum clearly shows the presence of two different species of CuII, which can be 
distinguished based on their g-parallel values. 
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Figure 4.3.  EPR spectrum of 4:1 CuII-(250.0 μM) Hn5 in DMF.  The estimated g values 
are 2.313 and 2.082 for g-parallel and g-perpendicular, respectively. 
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data was acquired on the INOVA500 Varian spectrometer with a bio-triple resonance 5 
mm probe at 25 ºC.  Up to 6.0 equivalents of CoII were added to the peptide in small 
increments.  No signal was observed upon addition of 0.5 equivalent of CoII within the 
monitoring spectral region (–150 to 150 ppm).  At 1.5 equivalents, three very weak 
signals can be observed at ~50, ~60, and ~70 ppm, which can be clearly seen at 2.0 
equivalents of CoII (Figure 4.4).  The two signals at 58 and 67 ppm are broader compared 
to a relatively sharp signal at 50 ppm.  A new signal appears approximately at 48  
ppm after 2.5 equivalents of CoII, and continued addition of CoII up to 6.0 equivalents 
only enhances the intensity of the shifted signals.  The typical chemical shift range for 
CoII-bound imidazole group of histidine residue is approximately from 40–80 ppm.51  
Addition of 30.0 uL D2O to the sample significantly reduces the signal intensity, which 
clearly shows these signals to be the solvent-exchangeable imidazole NH protons.  Thus, 
the signals observed may be assigned to the CoII-bound histidine residues on Hn5.   
An important observation from this experiment is the indication that there are 
only two types of metal binding modes.  From 0.5 to 2.5 equivalents of CoII, one binding 
mode of CoII-Hn5 can be seen from a simultaneous increase of signal intensity at 50, 58, 
and 67 ppm.  A second mode of metal binding becomes observable starting at 2.5 
equivalents of CoII, showing a new signal at 47 ppm and no additional signals are 
observed up to 6.0 equivalents of CoII.  The three signals from the first binding mode may 
be assigned to His-15, His-18, and His-19 in the HEXXH motif, since there is only one 
histidine in the ATCUN motif.  In the ATCUN motif, the metal is bound through the 
 185
 Figure 4.4.  1H NMR spectra of CoII-Hn5 at 2:1 (bottom) and 6:1 (top) ratios with 8k 
scans.  Up to 2.5 equivalents of CoII, only three signals at 50, 58, and 67 ppm are 
observed, and from 2.5 to 6.0 equivalents of CoII, a new signal at 47 ppm appears.  All 
signals are solvent-exchangeable (i.e.  determined by signal reductions after D2O 
addition).  The three signals may represent one metal binding mode by 3 histidine 
residues in HEXXH motif, and the latter signal at 47 ppm may be assigned to a single 
histidine residue in ATCUN motif. 
 186
amide backbones of the first three amino acids and the imidazole group of 3His.  Thus, a 
single signal from the second binding mode may be assigned to the ATCUN site. 
Different concentrations of catechol were incubated with 5.0 μM CuII-Hn5 (4:1) 
in 100.0 mM HEPES buffer at pH 7.0 and 25 ºC.  An increase in the rate of catechol 
oxidation was observed with increasing substrate, which reaches saturation at higher 
concentrations of catechol (Figure 4.5).  The saturation profile suggests the presence of 
enzyme-like kinetics, and the rate law can be described according to the following 
equations, with the assumption that [CA] >> [Cu(II)-Hn5-CA]:   
 
[Cu(II)-Hn5-CA][Cu(II)-Hn5] + [CA] [Cu(II)-Hn5] + o-quinone
k1
k-1
kcat
 
[ ]
[ ]CAK
CAV
Hn
Max
+= 50
ν  (1) 
where υ0 and VMax are the measured and maximum velocity, respectively, and 
1
1
5 k
kkK catHn −
+=  is the virtual dissociation constant of the CuII-Hn5-CA complex.  The 
data can be well fitted to Eq. 1 to afford KHn5, the first-order rate constant or the turnover 
number kcat (kcat = VMax/[CuII-Hn5]), and the second-order rate constant or the catalytic 
efficiency kcat/KHn5 of 3.06 × 10–3 M, 4.53 × 10–2 s–1, and 14.83 M–1 s–1, respectively 
(Figure 4.5).  Compared to the auto-oxidation rate of catechol (4.74 × 10–7 s–1) in the 
absence of CuII-Hn5,45 there is a 9.56 × 104-times rate acceleration with respect to the 
first-order rate constant. 
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Figure 4.5.  Catechol oxidation by CuII-Hn5 (4:1) in 100.0 mM HEPES at pH 7.0 and 25 
ºC.  The saturation profile suggests a possible pre-equilibrium kinetics.  The data are 
fitted to Eq. 1, an analogue of Michaelis-Menten equation, to afford KHn5, kcat, and 
kcat/KHn5. 
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Since CuII-Hn5 can oxidize catechol, the CuII binding to Hn5 was monitored with 
catechol oxidation.  Different amounts of CuII (0–16.0 equivalents) were incubated with 
5.0 μM Hn5 and 5.0 mM catechol/MBTH in 100 mM HEPES buffer at pH 7.0 and 25 ºC.  
From 0–1.0 equivalent of CuII, no significant activation was observed (Figure 4.6).  
However, a sudden increase in the activity was observed after the first equivalent of CuII 
and does not reach saturation until 16.0 equivalents of metal.  Since Hn5 has multiple 
metal binding residues and two proposed metal binding sites on the sequence, the peptide 
may bind the CuII ion in such a way that no binding site is left open for substrate 
interaction.  In the presence of more CuII, however, more substrate binding sites can 
become available.  As a result, the 1:1 CuII-Hn5 species appears inactive, and an abrupt 
increase in the activity is observed at higher CuII concentrations. 
 The interaction between the CuII-Hn5 complex and the catechol was confirmed by 
an optical binding study with a slow substrate, 4,5-dichlorocatechol (DCC).  The activity 
of DCC is roughly 200 times slower than catechol with respect to kcat as a ligand.45  A 
1.0-mL solution of 200-μM CuII-Hn5 was slowly titrated with DCC in DMF at 25 °C.  
The formation of complex was monitored from 200–800 nm on the Varian Cary50 Bio 
UV-Vis spectrophotometer.  Upon addition of DCC, a new absorption corresponding to a 
complex between CuII-Hn5 and DCC appears at 298 nm (Figure 4.7).  The plot of the 
(CuII-Hn5)-DCC complex against equivalents of DCC added shows the binding to reach a 
saturation at approximately 3.0 equivalents of DCC.  The results suggest a possible 
presence of three metal binding sites for substrate binding.
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Figure 4.6.  CuII binding of Hn5 monitored with catechol oxidation activity.  No 
significant activity was observed approximately up to 1.0 equivalent of CuII, which is 
followed by a sudden increase in the activity for subsequent assays. 
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 In the presence of H2O2, a significant rate enhancement in catechol oxidation was 
observed for the CuII-Bc system in the previous chapter.  Similar experiments were 
performed to determine the effect of H2O2 on catechol oxidation by CuII-Hn5.  Different 
concentrations (0–64.0 mM) of H2O2 were incubated with 0.5 μM CuII-Hn5 and 3.2 mM 
catechol in 100.0 mM HEPES buffer at pH 7.0 and 25 ºC.  The increase in catechol 
oxidation was observed with increasing H2O2 and reaches saturation at higher 
concentrations of H2O2 (Figure 4.8 inset).  The saturation profile indicates a possible 
presence of a pre-equilibrium kinetics, suggesting H2O2 as another substrate capable of 
interaction with the metal center(s).  The data can be fitted to Eq. 2 to afford an apparent 
binding or dissociation constant KH2O2 of 8.63 × 10–3 M for H2O2.   
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Background ++=νν                    (2) 
This compared to KHn5 = 3.06 × 10–3 M, the binding constant for catechol in the absence 
of H2O2, is approximately 2.8 times higher, suggesting that this substrate binds ~3× lower 
than catechol toward the CuII-Hn5 complex. 
The fact that both substrates can independently bind to the CuII center (i.e.  both 
catechol and H2O2 show saturation), it is essential to determine how the binding of one 
affects the other.  Different concentrations (0–6.4 mM) of catechol were incubated with 
the CuII-Hn5 (0.2 μM) in the presence of different H2O2 concentrations (0–64.0 mM).  
The enhancements in activity of catechol oxidation in the presence of H2O2 were clearly 
observed (Figure 4.8).  While KHn5 is increased by ~2 folds, the addition of 32.0 mM  
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Figure 4.7.  4,5-dichlorocatechol binding of CuII-Hn5 in DMF.  All the spectra have been 
zeroed with that of CuII-Hn5 complex alone.  The (CuII-Hn5)-DCC complex plotted 
versus DCC added shows saturation at 3.0 equivalents of DCC.
 192
H2O2 in the assay increased both the kcat and kcat/KHn5 by 7 and 4 folds, respectively.  
Because the two substrates may bind to CuII-Hn5 independently of each other, the Hanes 
plot analysis can be used to determine the interaction between the two substrates. 
From the Hanes analysis, the apparent binding equilibrium constants for both 
substrates and an intrinsic binding constant for one substrate can be calculated.52  The 
Hanes analysis requires an initial linear treatment of the data in Figure 4.8 according to 
the following rate law (Eq. 3), 
[ ] [ ] [ ] [ ]⎟⎟⎠
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where  is the intrinsic binding constant for H2O2,  and  are the 
apparent binding constants for H2O2 and catechol, and 
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CatecholK
ν  and  are the experimental 
and maximum velocity, respectively (Figure 4.9 A).  The ratio between the corresponding 
apparent and intrinsic equilibrium constants for each substrate can suggest how the 
binding of one substrate affects the binding of another.  The secondary plots of the fitted 
y-intercept (Eq. 4) and slope (Eq. 5) values versus 1/[H2O2] afford the two apparent 
equilibrium constants  = 5.23 × 10–3 M and  = 3.63 × 10–3 M and the 
intrinsic binding constant  = 2.26 × 10–3 M (Figure 4.9 B and C). 
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Figure 4.8.  Hydrogen peroxide influence on catechol oxidation by 0.2 μM CuII-Hn5 at 
pH 7.0 in 100.0 mM HEPES buffer at 25 °C.  The concentrations of H2O2 were varied 
from 0 to 64.0 mM.  The titration of H2O2 at a constant catechol concentration of 3.2 mM 
displays saturation, which indicates the direct interaction between the CuII-Hn5 center 
and H2O2 (the inset). 
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The ratio between the apparent and intrinsic binding constants is 1.19 for catechol 
(  /KHn5) and 2.31 for H2O2 ( / ), suggesting that the binding of H2O2 to 
the CuII-Hn5 complex does not affect the catechol binding; whereas, the binding of H2O2 
is reduced by half in the presence of catechol. 
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Figure 4.9.  Hanes analysis of the oxidation of catechol by CuII-Hn5 at different 
concentrations of H2O2 (kinetic data from Figure 4.8).  Plot B and C are the replots of the 
slope and y-intercept values from plot A with respect to [H2O2]–1.  The apparent binding 
equilibrium constants for catechol ( ) and H2O2 ( ) as well as the intrinsic 
binding constant for H2O2 ( ) can be determined from the secondary plots.
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4.4 Conclusions 
In this study, the oxidative activity of Hn5 peptide in the presence of CuII has 
been studied.  Recent results have shown the ability of short N-terminal metal binding 
fragments Aβ (i.e.  A peptide of 1–40 or 1–42 amino acids isolated from the plaques of 
Alzheimer’s disease patients.), Aβ1–16 and Aβ1–20, can perform catechol- and phenol-
oxidase-like chemistry in the presence of CuII.45, 46  Furthermore, in the previous chapter I 
have shown catechol oxidation chemistry of the CuII complex of bacitracin, a 
dodecapeptide antibiotic.  While the CuII-Aβ complexes oxidize catechol to o-quinone 
through a di-CuII center catalysis, the CuII-Bc complex only requires a mononuclear CuII 
center.  Both systems bind to CuII in a 1:1 ratio.  Nevertheless, two CuII-Aβ complexes 
have been proposed to assemble into a di-CuII center either by the substrate or oxygen 
during catalysis.45, 46  Thus, it will be interesting to determine how will the Hn5 peptide, 
having two or more potential metal binding sites within per peptide sequence, perform 
catechol oxidation in the presence of redox-active CuII. 
The CuII complex of Hn5 has been shown to effectively oxidize catechol with a 
rate enhancement of 9.56 × 104 times with respect to the first-order rate constant, 
compared to the auto-oxidation rate of catechol (4.74 × 10–7 s–1).45  For CuIIAβ45 and 
CuII-Bc, the presence of H2O2 significantly enhances the catechol oxidation.  H2O2 also 
significantly enhances the catechol oxidation by CuII-Hn5.   
The preliminary results from the above studies only suggest the ability of CuII-
Hn5 to perform catechol oxidation.  According to EPR and NMR studies, there are two 
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potential metal binding sites on Hn5.  Because the metal binding sites are on the same 
peptide, they may be in close enough proximity to perform a di-CuII oxygen chemistry.  
However, more studies are necessary to differentiate between the mononuclear and 
dinuclear CuII center.  Thus, experiments such as optical DCC binding and catechol 
binding (i.e.  with respect to activity) using the Job method can provide further evidence.  
In addition, similar studies with EPR and NMR spectroscopic techniques may provide 
more details on substrate binding; whereas, all the above studies under anaerobic 
conditions can provide a clear picture for the role played by dioxygen. 
In conclusion, redox-active metals such as CuII and FeIII are essential for 
biological processes but are heavily regulated due to oxidative damages they can impose 
on the biological molecules.53  Dysregulation of metal ions have been associated with 
many human pathologies, such as amyotrophic lateral sclerosis, Wilson’s, Alzheimer’s, 
and Parkinson’s disease, just to name a few.54  There seems to be a trend among some 
biologically available peptides, where they can effectively bind a wide range of metal 
ions.55  It is possible that these metal binding peptides play an important role in the 
regulation of these redox metals.  Thus, understanding of the oxidation chemistry of these 
metal-peptide complexes may be essential to better understanding of related pathologies.  
Even though the findings in this dissertation may not be directly extended to in vivo 
situations, they are intended for providing fundamental understandings in hopes of 
serving as a building block for future innovations. 
 
 199
                                                                                                                                                 
References 
 
1 Wennergren, G.; Lagercrantz, H.  “One sometimes finds what one is not looking for” 
(Sir Alexander Fleming):  the most important medical discovery of the 20th century.  
Acta Paediatrica, 2007, 96, 141–144. 
2 Raju, T. N. K.  The Nobel Chronicles 1945:  Sir Alexander Fleming (1881–1955); Sir 
Ernst Boris Chain (1906–79); and Baron Howard Walter Florey (1898–1968).  The 
Lancet, 1999, 353, 936. 
3 (a) Ming, L.-J.  Structure and function of “metalloantibiotics”.  Med. Res. Rev., 2003, 
23, 697–762.  (b) Burger, R. M.  Nature of activated bleomycin.  Struct. Bond, 2000, 
97, 287–303.  (c) Claussen C. A.; Long, E. C.  Nucleic acid recognition by metal 
complexes of bleomycin.  Chem. Rev., 1999, 99, 2797–2816.  (d) Burger R. M.  
Cleavage of nucleic acids by bleomycin.  Chem. Rev., 1998, 98, 1153–1170.  (e) Hecht, 
S. M.  RNA degradation by bleomycin, a naturally occurring bioconjugate.  Bioconj. 
Chem., 1994, 5, 513–526.  (f) Hüttengofer, A.; Hudson, S.; Noller, H. F.; Mascharak, P. 
K.  Cleavage of tRNA by Fe(II)-bleomycin.  J. Biol. Chem., 1992, 267, 24471–24475. 
4 Zhang, L.; Dhillon, P.; Yan, H.; Farmer, S.; Hancock, R. E. W.  Interactions of bacterial 
cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas 
aeruginosa.  Antimicrobial Agents and Chemotherapy, 2000, 44, 3317–3321. 
 200
                                                                                                                                                 
5 Buynak, J. D.  Cutting and stitching:  the cross-linking of peptidoglycan in the 
assembly of the bacterial cell wall.  JACS Chem. Bio., 2007, 2, 602–605. 
6 (a) Connell, S. R.; Tracz, D. M.; Nierhaus, K. H.; Taylor, D. E.  Ribosomal protection 
proteins and their mechanism of tetracycline resistance.  Antimicrobial Agents and 
Chemotherapy, 2003, 47, 3675–3681.  (b) Smythies, J. R.; Benington, F.; Morin, R. D.  
On the molecular mechanism of action of the tetracyclines.  Experientia, 1972, 28, 
1253–1254. 
7 Zinner, S. H.  Antibiotic use:  present and future.  New Microbiologica, 2007, 30, 321–
325. 
8 Amyes, S. G. B.  Enterococci and streptococci.  Int. J. Antimicro. Agents, 2007, 29, 
S43–S52. 
9 (a) Kollef, M. H.  Limitations of vancomycin in the managements of resistant 
staphylococcal infections.  Clinical Infectious Diseases, 2007, 45, S191–S195.  (b) 
Deresinski, S.  Counterpoint:  vancomycin and Staphylococcus aureus––an antibiotic 
enters obsolescence.  Clinical Infectious Diseases, 2007, 44, 1543–1548. 
10 (a) Zaiou, M.  Multifunctional antimicrobial peptides:  therapeutic targets in several 
human diseases.  J. Mol. Med., 2007, 85, 317–329.  (b) Mor, A.  Peptides, 
antimicrobial.  In editor(s); Ed.  Kirk-Othmer Encyclopedia of Chemical Technology 
(5th Edition).  Publisher:  city, country, 2006.  (c) Smet, K. D.; Contreras, R.  Human 
antimicrobial peptides:  defensins, cathelicidins and histatins.  Biotech. Letters, 2005, 
 201
                                                                                                                                                 
27, 1337–1347.  (d) Kamysz, W.; Okrój, M.; Łukasiak, J.  Novel properties of 
antimicrobial peptides.  Acta Biochimica Polonica, 2003, 50, 461–469.  (e) Hancock, R. 
E. W.; Diamond G.  The role of cationic antimicrobial peptides in innate host defences.  
Trends in Microbiology, 2000, 8, 402–410. 
11 (a) Zaiou, M.; Gallo, R. L.  Cathelicidins, essential gene-encoded mammalian 
antibiotics.  J. Mol. Med. 2002, 80, 549–561. (b) Gantz, T.  Defensins and host defense.  
Science 1999, 286, 420–421. 
12 (a) Ganz, T.  Defensins.  Eur. J. Haematol. 1990, 44, 1–8.  (b) Raj, P. A.; Marcus, E.; 
Sukumaran, D. K.  Structure of human salivary histatin 5 in aqueous and nonaqueous 
solutions.  Biopolymers 1998, 45, 51–67.  (c) Turner, J.; Cho, Y.; Dinh, N. N.; Waring, 
A. J.; Lehrer, R. I.  Activities of LL–37, a cathelin-associated antimicrobial peptide of 
human neutrophils.  Antimicrob. Agents Chemother. 1998, 42, 2206–2214. 
13 Park, C. B.; Kim, H. S.; Kim, S. C.  Mechanism of action of the antimicrobial peptide 
buforin II:  buforin II kills microorganisms by penetrating the cell membrane and 
inhibiting cellular functions.  Biochem. Biophys. Res. Comm. 1998, 244, 253–257. 
14 Gough, M.; Hancock, R. E.; Kelly, N. M.  Antiendotoxic potential of cationic peptide 
antimicrobials.  Infect. Immun. 1996, 64, 4922–4927. 
15 (a) Bennick, A.  Extraoral functions of salivary proteins.  J. Oral Biosci., 2007, 49, 
24–26.  (b) Cai, K.; Bennick, A.  Effect of salivary proteins on the transport of tannin 
and quercetin across intestinal epithelial cells in culture.  Biochem. Pharm., 2006, 72, 
 202
                                                                                                                                                 
974–980.  (c) Shimada, T.  Salivary proteins as a defense against dietary tannins.  J. 
Chem. Ecol., 2006, 32, 1149–1163. 
16 Fidel, P. L.; Huffnagle, G. B.; Eds.  FUNGAL IMMUNOLOGY:  From an Organ 
Perspective.  Springer Science:  New York, NY, 2005. 
17 (a) Powderly, W. G.; Mayer, K. H.; Perfect, J. R.  Diagnosis and treatment of 
oropharyngeal candidiasis in patients infected with HIV:  A critical reassessment.  
AIDS Res. Human Retroviruses, 1999, 15, 1405–1412.  (b) Greenspan, D.  Treatment of 
oral candidiasis in HIV infection.  Oral Surg. Oral Med. Oral Pathol., 1994, 78, 211–
215. 
18 (a) Shen, Y. Z.; Qi, T. K.; Ma, J. X.; Jiang, X. Y.; Wang, J. R.; Xu, Q. N.; Huang, Q.; 
Liu, X. N.; Sun, H. Q.; Lu, H. Z.  Invasive fungal infections among inpatients with 
acquired immune deficiency syndrome at a Chinese university hospital.  Mycoses, 
2007, 50, 475–480.  (b) Taylor, B. N.; Fichtenbaum, C.; Saavedra, M.; Slavinsky III, J.; 
Swoboda, R.; Wozniak, K.; Arribas, A.; Powderly, W.; Fidel Jr., P. L.  In vivo 
virulence of Candida albicans isolates causing mucosal infections in people infected 
with the human immunodeficiency Virus.  J. Infect. Dis., 2000, 182, 955–999.  (c) 
Tumbarello, M.; Tacconelli, E.; de Gaetano Donati, K.; Morace, G.; Fadda, G.; Cauda, 
R.  Candidemia in HIV-infected subjects.  Eur. J. Clin. Microbiol. Infect. Dis., 1999, 
18, 478–483.  (d) Makarova, N. U.; Pokrowsky, V. V.; Kravchenko, A. V.; 
Serebrovskaya, L. V.; James, M. J.; McNeil, M. M.; Lasker, B. A.; Warnock, D. W.; 
 203
                                                                                                                                                 
Reiss, E.  Persistence of oropharyngeal candida albicans straits with reduced 
susceptibilities to fluconazole among human immunodeficiency virus-seropositive 
children with adults in a long-term care facility.  J. Clin. Microbiol., 2003, 41, 1833–
1837.  (e) Müller, F.-M. C.; Groll, A. H.; Walsh, T. J.  Current approaches to diagnosis 
and treatment of fungal infections in children infected with human immuno deficiency 
virus.  Eur. J. Pediatr., 1999, 158, 187–199. 
19 Cannon, R. D.; Lamping, E.; Holmes, A. R.; Niimi, K.; Tanabe, K.; Niimi, M.; Monk, 
B. C.  Candida albicans drug resistance – another way to cope with stress.  
Microbiology, 2007, 153, 3211–3217. 
20 Holbrook, I. B.; Molan, P. C.  The identification of a peptide in human parotid saliva 
particularly active in enhancing the glycolytic activity of the salivary micro-organisms.  
Biochem. J., 1975, 149, 489–492. 
21 Oppenheim, F. G.; Yang, Y.-C.; Diamond, R. D.; Hyslop, D.; Offner, G. D.; Troxler, 
R. F.  The primary structure and functional characterization of the neutral histidine-rich 
polypeptide from human parotid secretion.  J. Biol. Chem., 1986, 261, 1177–1182. 
22 Oppenheim, F. G.; Xu, T.; McMillian, F. M.; Levitz, S. M.; Diamond, R. D.; Offner, 
G. D.; Troxler, R. F.  Histatins, a novel family of histidine-rich proteins in human 
parotid secretion.  J. Biol. Chem., 1988, 263, 7472–7477. 
 204
                                                                                                                                                 
23 Hay, D. I.  Fractionation of human parotid salivary proteins and the isolation of an 
histidine-rich acidic peptide which shows high affinity for hydroxyapaptite surfaces.  
Arch. Oral Biol., 1975, 20, 553–558. 
24 Baum, B. J.; Bird, J. L.; Longton, R. W.  Polyacrylamide gel electrophoresis of human 
salivary histidine-rich-polypeptides.  J. Dent. Res., 1977, 56, 1115–1118. 
25 MacKay, B. J.; Denepitiya, L.; Iacono, V. J.; Krost, S. B.; Pollock, J. J.  Growth-
inhibitory and bactericidal effects of human parotid salivary histindine-rich 
polypeptides on streptococcus mutans.  Infect. Immun., 1984, 695–701. 
26 Pollock, J. J.; Denepitiya, L.; MacKay, B. J.; Iacono, V. J.  Fungistatic and fungicidal 
activity of human parotid salivary histidine-rich polypeptides on candida albicans.  
Infect. Immun., 1984, 44, 702–707. 
27 Tsai, H.; Bobek, L. A.  Human salivary histatin-5 exerts potent fungicidal activity 
against Cryptococcus neoformans.  Biochim. Biophys. Acta, 1997, 1336, 367–369. 
28 Tsai, H.; Bobek, L. A.  Studies of the mechanism of human salivary histatin-5 
candidacidal activity with histatin-5 variants and azole-sensitive and –resistant candida 
species.  Antimicro. Agents Chemo., 1997, 41, 2224–2228. 
29 Sabatini, L. M.; Ota, T.; Azen, E. A.  Nuleotide sequence analysis of the human 
salivary protein genes HIS1 and HIS2, and evolution of the STATH/HIS gene family.  
Mol. Biol. Evol., 1993, 10, 497–511. 
 205
                                                                                                                                                 
30 Vanderspek, J. C.; Wyandt, H. E.; Skare, J. C.; Milunsky, A.; Oppenheim, F. G.; 
Troxler, R. L.  Localization of the genes for histatins to human chromosome 4q13 and 
tissue distribution of the mRNAs.  Am. J. Hum. Genet., 1989, 45, 381–387. 
31 Xu, L.; Lai, K.; Santarpia, R. P.; Pollock, J. J.  Salivary proteolysis of histidine-rich 
polypeptides and the antifungal activity of peptide degradation products.  Arch. Oral 
Biol., 1993, 38, 277–283. 
32 Raj, P. A.; Edgerton, M.; Levine, M. J.  Salivary histatin 5:  dependence of sequence, 
chain length, and helical conformation for candidacidal activity.  J. Biol. Chem., 1990, 
265, 3898–3905. 
33 Raj, P. A.; Soni, S.-D.; Levine, M. J.  Membrane-induced helical conformation of an 
active candidacidal fragment of salivary histatins.  J. Biol. Chem. 1994, 269, 9610–
9619. 
34 Edgerton, M.; Koshlukova, S. E.; Lo, T. E.; Chrzan, B. G.; Straubinger, R. M.; Raj, P. 
A.  Candidacidal activity of salivary histatins.  J. Biol. Chem., 1998, 273, 20438–
20447. 
35 Koshlukova, S. E.; Lloyd, T. L.; Araujo, M. W. B.; Edgerton, M.  Salivary histatin 5 
induces non-lytic release of ATP from candida albicans leading to cell death.  J. Biol. 
Chem.¸ 1999, 274, 18872–18879. 
 206
                                                                                                                                                 
36 Li, X. S.; Reddy, M. S.; Baev, D.; Edgerton, M.  Candida albicans Ssa1/2p is the cell 
envelope binding protein for human salivary histatin 5.  J. Biol. Chem. 2003, 278, 
28553–28561. 
37 Baev, D.; Rivetta, A.; Vylkova, S.; Sun. J. N.; Zeng, G.-F.; Slayman, C. L.; Edgerton, 
M.  The TRK1 potassium transporter is the critical effector for killing of Candida 
albicans by the cationic protein, histatin 5.  J. Biol. Chem. 2004, 279, 55060–55072. 
38 (a) Helmerhorst, E. J.; Troxler, R. F.; Oppenheim, F. G.  The human salivary peptide 
histatin 5 exerts its antifungal activity through the formation of reactive oxygen species.  
Proc. Nat. Acad. Sci., 2001, 98, 14637–14642.  (b) Helmerhorst, E. J.; Breeuwer, P.; 
van’t Hof, W.; Walgreen-Weterings, E.; Oomen, L. C. J. M.; Veerman, E. C. I.; 
Amerongen, A. V. N.; Abee, T.  The cellular rarget of histatin 5 on candida albicans is 
the energized mitochondrion.  J. Biol. Chem., 1999, 274, 7286–7291. 
39 Peters Jr., T.  Interaction of one mole of copper with the alpha amino group of bovine 
serum albumin.  Biochim. Biophys. Acta 1960, 39, 546–547. 
40 Vallee, B. L.; Coleman, J. E.; Auld, D. S.  Zinc fingers, zinc clusters, and zinc twists 
in DNA-binding protein domains.  Proc. Natl. Acad. Sci. USA 1991, 88, 999–1003. 
41 (a) Brewer, D; Lajoie, G.  Evaluation of the metal binding properties of the histidine-
rich antimicrobial peptides histatins 3 and 5 by electrospray ionization mass 
spectrometry.  Rqpid Comm. Mass Spec., 2000, 14, 1736–1745. 
 207
                                                                                                                                                 
42 Gusman, H.; Lendenmann, U.; Grogan, J.; Troxler, R. F.; Oppenheim, F. G.  Is 
salivary histatin 5 a metallopeptide?  Biochim. Biophy. Acta, 2001, 1545, 86–95. 
43 Melino, S.; Gallo, M.; Trotta, E.; Mondello, F.; Paci, M.; Petruzzelli, R.  Metal-
binding and nuclease activity of an antimicrobial peptide analogue of the salivary 
histatin 5.  Biochemistry, 2006, 45, 15373–15383. 
44 Cabras, T.; Patamia, M.; Melino, S.; Inzitari, R.; Messana, I.; Castagnola, M.; 
Petruzzelli, R.  Pro-oxidant activity of histatin 5 related Cu(II)-model peptide probed by 
mass spectrometry.  Biochem. Biophy. Res. Comm., 2007, 358, 277–284. 
45 da Silva, G. F. Z.; Ming, L.-J.  Alzheimer’s disease related copper(II)-β-amyloid 
peptide exhibits phenol monooxygenase and catechol oxidase activities.  Angew. Chem. 
Int. Ed. 2005, 44, 5501–5504. 
46 da Silva, G. F. Z.; Tay, W. M.; Ming, L.-J.  Catechol oxidase-like oxidation chemistry 
of the 1–20 and 1–16 fragments of Alzheimer’s disease-related β-amyloid peptide:  
their structure-activity correlation and the fate of hydrogen peroxide.  J. Biol. Chem. 
2005, 280, 16601–16609. 
47 Srivatsan, S. G.; Nigam, P.; Rao, M. S.; Verma, S.  Phenol oxidation by copper-
metallated 9-allyladenine-DVB polymer: reaction catalysis and polymer recycling.  
Applied Catalysis A 2001, 209, 327–334. 
 208
                                                                                                                                                 
48 Inubushi, T.;Becker, E. D.  Efficient Detection of Paramagnetically Shifted NMR 
Resonances by Optimizing WEFT Pulse Sequence.  J. Magn. Reson. 1983, 51, 128–
133. 
49 Casella, L.; Gullotti, M.; Pacchioni, G.  Coordination Modes of Histidine.  3.  
Stereochemistry of Copper(II) Complexes Related to Pyridoxal Catalysis.  J. Amer. 
Chem. Soc. 1982, 104, 2386–2396. 
50 (a) Bertini, I.; Luchinat, C.; Parigi, G.  Solution NMR of Paramagnetic Molecules; 
Elsevier Science B.V.:  Amsterdam, The Netherlands, 2001.  (b) Ming, L.-J.  Nuclear 
Magnetic Resonance of Paramagnetic Metal Centers in Proteins and Synthetic 
Complexes.  In Physical Methods in Bioinorganic Chemistry:  Spectroscopy and 
Magnetism.  Que, Jr. L., Ed.; University Science Books:  Sausalito, 2000. 
51 (a) Hannan, J. P.; Whittaker, S. B.-M.; Hemmings, A. M.; James, R.; Kleanthous, C.; 
Moore, G. R.  NMR studies of metal ion binding to the Zn-finger-like HNH motif of 
colicin E9.  J. Inorg. Biochem. 2000, 79, 365–370.  (b) Salgado, J.; Kalverda, A. P.; 
Diederix, R. E. M.; Canters, G. W.; Moratal, J. M.; Lawler, A. T.; Dennison, C.  
Paramagnetic NMR investigations of Co(II) and Ni(II) amicyanin.  J. Biol. Inorg. 
Chem. 1999, 4, 457–467. 
52 (a) Segel, I. H.  Steady-State Kinetics of Multireactant Enzymes.  Enzyme Kinetics:  
Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems.  John 
 209
                                                                                                                                                 
Wiley & Sons, Incs.:  New York, 1993.  (b) Leskovac, V.  Comprehensive Enzyme 
Kinetics, Kluwer/Plenum, Boston, 2002, p. 119. 
53 Gaggelli, E.; Kozlowski, H.; Valensin, D.; Valensin, G.  Copper homeostasis and 
neurodegenerative disorders (Alzheimer’s, Prion, and Parkinson’s diseases and 
amyotrophic lateral scleosis).  Chem. Rev. 2006, 106, 1995–2004. 
54 Gaggelli, E.; Kozlowski, H.; Valensin, D.; Valensin, G.  Copper homeostasis and 
neurodegenerative disorders (Alzheimer’s, Prion, and Parkinson’s diseases and 
amyotrophic lateral sclerosis).  Chem. Rev. 2006, 106, 1995–2044. 
55 (a) Long, E. C.  Ni(II)-Xaa-Xaa-His metallopeptide––DNA/RNA interactions.  Acc. 
Chem. Res. 1999, 32, 827–836.  (b) Ghosh, D.; Pecoraro, V. L.  Probing metal–protein 
interactions using a de novo design approach.  Curr. Opin. Chem. Biol. 2005, 9, 97–
103.  (c) Walkup, G. K.; Imperiali, B.  Fluorescent chemosensors for divalent zinc 
based on zinc finger domains.  Enhance oxidative stability, metal binding affinity, and 
structural and functional characterization.  J. Am. Chem. Soc. 1997, 119, 3443–3450.  
(d) Cowan, J. A.; Jin, Y.  DNA cleavage by copper–ATCUN complexes.  Factors 
influence cleavage mechanism and linearization of dsDNA.  J. Am. Chem. Soc. 2005, 
127, 8408–8415. 
 
 
 
 
 
ABOUT THE AUTHOR 
 
 William Maung Tay was born in 1979 in Rangoon, Burma (currently known as 
Yangon, Myanmar).  He immigrated to the United States of America at the age of 12.  
After overcoming the language barrier, he graduated with high honor with distinction 
from Lakeland Senior High School.  He attended Florida Southern College from 1998 to 
2002 and graduated with a B.Sc. in both chemistry and mathematics.  Then, he pursued 
his graduate studies in chemistry at the University of South Florida under the supervision 
of Dr. Li-June Ming.  From 2002 to 2004, he served as a teaching assistant for General 
and Organic Chemistry Labs.  Then, he took on the NMR teaching assistant position from 
2004 to 2007. 
